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INTRODUCTION 
Helicobacter pylori or Campylobacter pylori as earlier known , is possibly the most 
common human infection. It has been strongly linked to numerous gastro intestinal 
disorders ranging from non-ulcer dyspepsia to gastric malignancies. There is a 
wide geographical and ethnic distribution in the infection rate.  Certain ethnic 
groups such as Africans and Hispanics have a much higher rate of infection. In 
general, people belonging to developing nations have a higher infection rate as 
compared to their counterparts in developed nations. The epidemiology of 
Helicobacter pylori infection in India is different from those in developed 
countries. The main difference lies in the early age of colonization , overt 
manifestation and high chances of re-infection with the bacteria. It was believed 
for a long time in the field of medicine that gastroduodenal ulceration was due to 
high levels of stress but it is now proven that it is this bacterium that lies at the core 
of causation of acid peptic disorder , gastric malignancies and gastrointestinal 
lymphoma.  
 
 
 
  
AIM OF THE STUDY 
The present study undertaken aims at 
1. Determining the prevalence of Helicobacter pylori infection in patients with 
Acid peptic Disease and its resultant sequelae.  
2. Emphasizing the association of Helicobacter pylori with complications of 
peptic ulcer disease and the need for instituting anti H.pylori treatment for 
symptomatic cases. 
 
 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
STUDY SUBJECTS 
100 Patients visiting the outpatient Department and those admitted as 
inpatients in Government Rajaji Hospital , Madurai with complaints of dyspepsia 
and abdominal pain consistent with Acid Peptic Disease or its resultant acute or 
chronic sequelae were selected at random. Institutional Ethical Committee 
Clearance was obtained and Informed Consent was obtained from the study 
subjects prior to subjecting them to any interrogation or investigation. 
METHOD USED 
 Instant- ViewR H.pylori Whole Blood/Serum Cassette Test manufactured by 
Alfa Scientific Designs Inc. was used for serological testing of patients to detect 
IgG antibodies to Helicobacter pylori. This commercially available kit has 
sensitivity of 95.1% and specificity of 94.1%. (Information supplied by the 
manufacturer). The whole blood test and serum test has comparably equivalent 
results. Upper Gastrointestinal Endoscopy was used to investigate the patients for 
the pathological process. 
 
 
  
TECHNIQUE 
 One drop of Whole Blood was added to the sample well. 30 seconds is 
allowed for the sample to get absorbed by the test strip. 3 drops of the provided 
diluent ( PBS diluents with 0.2% sodium azide) is added.  
PROCESS 
 The Test used is a “One Step Immunochromatography” technique. It detects 
Immunoglobulin type G directed against Helicobacter pylori in the human blood or 
extracted serum. The method employs a combination of anti-human 
immunoglobulin dye conjugate and highly purified Helicobacter pylori protein. As 
the sample flows through the absorbent paper, the anti-human immunoglobulin dye 
conjugate binds to the IgG antibody present in the sample. This complex binds to 
H.pylori protein in zone T and produces a coloured band. In the absence of 
antibodies , only the zone C changes colour due to the binding of unbound 
conjugate to a reagent fixed in zone C. This indicates proper performance of test 
but lack of IgG antibodies in the specimen added to the test strip. 
INTERPRETATION 
 If both C line and T line appear, it indicates that IgG antibodies specific to 
Helicobacter pylori are detected and the result is Positive. If only the C line 
appears, the result is Negative Strong positive results are seen in 2 to 3 minutes. 
  
Weak positive result can be seen upto 7 minutes. The results are not interpreted 
after 7 minutes. ( Fig. 1 , 2 ) 
PATIENT CATEGORIZATION 
• Patients with peptic ulcer type of pain but normal endoscopy were 
classified as Non-Ulcer Dyspepsia (NUD).  
• Those with edema or erythema of the mucosa were categorized as 
having Gastritis.  
• Also included were those patients with proven growth in the distal 
part of the stomach. 
 
 
 
 
 
 
 
 
  
HELICOBACTER PYLORI – THE PATHOGEN 
HISTORY 
 The spiral-shaped micro-organisms were described a century ago by 
Professor W. Jaworski from Poland. It was discovered in animals by G. Bizzazero. 
J.R. Warren of Australia who noted  spiral bacteria in the stomach. Robin Warren 
and B.J. Marshall performed a successful culture in 1982 . Initially called 
Campylobacter pyloridis, it was rechristened as Campylobacter pylori to be more 
grammatically apt in Latin terminology. Later ribosomal studies showed that the 
bacteria were not related to Campylobacter genus and hence the new genus 
Helicobacter was postulated. The name pylori denotes ‘of the pylorus’ which in 
Greek means ‘gatekeeper’. The Nobel Prize for Medicine was awarded to Barry J. 
Marshall and J. Robin Warren in 2005 for discovery of the bacterium and its 
pathological role in human disease. Genetic diversity data suggests that the 
bacteria had migrated from Africa about 58,000 years ago. This shows millennia of 
association between humans and Helicobacter pylori. Helicobacter pylori also 
holds a place of honour as being the first bacteria to be categorized as a Biological 
Carcinogen.1 
 
 
  
MICROBIOLOGY ( Ref. Fig.3,4 ) 
 Helicobacter pylori is a gram -ve helical or curved bacillus. It is about 3 
microns long and 0.5 microns in diameter. It is a fastidious, microaerophilic 
flagellate that has 4 to 6 lophotrichous flagellae which are composed of  two types 
of Flagellins.2 It contains the enzyme ‘Hydrogenase’ which oxidizes Hydrogen 
molecules produced by intestinal bacteria.3 It is also capable of forming Biofilms.4 
It also has the capability to change into a non-culturable coccoid5 form to offer 
survival advantage during adverse conditions. Helicobacter has the following 
culture needs 
• Culture temperature of 37 degree Celsius  
• Oxygen concentration of 5 to 10% ( Microaerophilic ) 
• Carbon di oxide concentration of 5 to 12% ( Capnophilic ) 
 H.pylori has 5 major outer membrane proteins (OMP). The major one being 
the family of proteins called Adhesins. The remaining 4 OMP’s include Porins, 
Iron transporters ,Flegellar proteins and some functionally unknown proteins. 
Common to all Gram – ve Bacteria , H.pylori also has a outer membrane bound 
Lipopolysaccharide (LPS). The O antigen on this membrane bound gycolipid can 
become fucosylated and resemble Lewis blood group antigen found in gastric 
mucosa.6 This may provide protection from immunological destruction.  
  
GENOMICS 
The genetic structure of H.pylori genome is highly geographically oriented both 
the core components and the flexible genome sequences. The genome sequence of 
Helicobacter pylori is 1.67 Mb long. Genomic study has revealed the presence of a 
40 kb long Cag Pathogenicity island that contains more than 40 different genes that 
are responsible for the pathogenicity of the bacteria. Absence of this pathogenicity 
island renders the strain avirulent and its carriers asymptomatic.7 Biologically 
active cagA gene leads to aggressive behavior of the bacterium with predisposition 
to intense ulceration of stomach and duodenum.8 An enzyme called SRC Kinase 
phosphorylates CagA protein which leads to activation of SHP2 phosphatase. This 
substance acts as an oncoprotein. This could be a plausible explanation on events 
leading to carcinomatous changes in stomach. Based on binding receptor 
differences, CagA is further divided into East-Asian CagA and Western CagA. The 
East Asian variant has greater biological activity compared to its counterpart , the 
Western CagA. Strains with more number of cagA tyrosine phosphorylase are 
linked to causation of stomach cancers.9 
Encoded by vacA gene, VacA protein has been proven to be an inducer of 
apoptosis in epithelial cells. It has been proposed that VacA protein is a potent 
immunomodulatory toxin. It suppresses local immunological response , thereby 
delaying the local clearance of the infection leading to persistence of local 
  
infection sans resistance . 10 The cytotoxin suppresses the local activation of 
immunologically competent T lymphocytes. However , the true involvement of 
this cytotoxin in the pathogenicity of Helicobacter pylori infection still remains a 
theory under debate and further research is underway.  
Mukhopadhyay et al.conducted a study in Calcutta. They demonstrated more 
than 70 strains of the bacteria. Among them, more than 90% had in them what is 
known as the cag Pathogenicity island.   This was a much higher prevalence than 
in the west or even East Asia for that matter.39 
Horizontal gene transfer and genome plasticity contribute to the evolution of 
pathogenic variants of Helicobacter pylori. Thus modern day Helicobacter 
harbours gene pools from ancestral populations that were from different continents 
and can be correlated with human migration. The laterally acquired genes offer 
survival advantage to organism in different hosts. The gain of Pathogenicity 
islands enables today’s bacteria to compete with native strains. For example, the 
South American strains are gradually disappearing and are being replaced by much 
more aggressive European strains. 
EVOLUTION 
 Helicobacter pylori migrated out of Africa about 58,000 years ago. Its 
evolution lead to 7 phenotypes. These can be broadly named as Europe ( isolated 
  
from Europe and India) , Africa 1  (from Africa), Africa 2 (from South Africa), 
East Asia , Asia 2 (from North India and Bangladesh), Maori (from Polynesia) and 
Amerind (from Native Americans). Mixing up of genomes occurred mainly due to 
colonization and slave trade. The study of genomic structure and evolutionary 
pattern of Helicobacter pylori has provided humans with extensive knowledge 
about the pattern of migration and settlement of our ancestors and origins of 
various races.  
There exists a bizarre entity in Helicobacter pylori known as 
“Microevolution”. This indicates evolutionary genomic changes occurring in an 
organism that is already in a state of active infection in a host. This occurs due to 
recombinant changes occurring in vivo. Mutation of cagA gene has been 
demonstrated by Aras et al11 in two samples taken from the same patient with a 
time interval of 7 years. Kersulyte et al12 has demonstrated deletion of cag island 
due to mutational changes. Such alterations may lead to loss of disease causing 
capacity.  
EPIDEMIOLOGY 
 Helicobacter pylori is the most widespread infection in the world. 
Developing countries have a much higher infection rates than Western countries. 
Also those in developing nations seem to acquire the infection at a much earlier 
  
age than their counterparts in developed nations.13 Infection at a younger age is 
likely to result in prolonged inflammation followed by gastric atrophy leading to 
higher risk of ulcer and cancer. The most important contributing factor responsible 
for this is the poor sanitary conditions in developing countries. People in the low 
socioeconomic strata are also prone to infection mainly due to poor sanitation.. 
Helicobacter has been positively associated with distal gastric adenocarcinoma and 
MALToma. It also has a negative association with reflux oesophagitis and 
oesophageal adenocarcinoma. An interesting fact is the recent revelation of 
involvement of the bacteria with numerous other systemic and auto-immune 
disorders such as ITP , dermatalogical conditions, hepatocellular diseases and 
cardiovascular diseases.14 
MODES OF TRANSMISSION 
 
 The bacteria has trophism for gastric type of mucosa and ingestion seems to 
be the most likely route, though this may occur by means of gastro-oral, Oro –Oral 
and Faeco-oral routes. Person to person contact is the most accepted mode of 
transfer.  Maternal infection confers 8 times risk and paternal infection carries 4 
times risk of the child acquiring infection.15 The Bacteria can be isolated from the 
blood, urine, faeces, saliva and dental plaques in infected individuals. The relative 
risk of infection increases according to the number of children who are reared 
under the same roof. The emphasis on the same household is because siblings and 
  
concordant twins brought up at separate homes from the time of birth do not show 
the same relative risk of acquiring the infection  
 The possibility of transmission between spouses remains controversial. The 
odds ratio of infection when one partner is infected in around 7.0. It depends on the 
number of years that they have lived together.16 
 Helicobacter pylori infection is sometimes categorized under Zoonosis. This 
school of thought arose from a few studies that demonstrated higher rate of 
infection in workers handling meat products that were raw.17 However this finding 
has been under question because of the fact that there may be immune mimicry 
between antibodies to H.pylori and antibodies against bacteria like Campylobacter 
jejuni.18 Dore et al. have shown higher prevalence in shepherds from a country 
called Sardinia. The same author has recovered H.pylori from sheep’s milk 
suggesting that sheep may be the ancient host of this ubiquitous bacteria. 19 There 
have also been reports of isolation of the bacteria from rhesus monkeys. 
Seroepidemiological studies examining relation between owning a pet and a higher 
H.pylori infection have failed to prove such association.20 
 Even the omnipresent housefly may be a vector for transmission of the 
organism. However , H.pylori could not be cultured from housefly forced to feed 
  
on human excreta containing Helicobacter, hence the concept of the common 
housefly being a possible vector for transmission is brought under question.21 
 Drinking water as a source of infection has been under debate. Klein et al. 
suggested that Peruvian children with unprotected water supply had 3 times the 
risk of infection compared to those with protected sources.22 In a Columbian study 
Goodman et al. showed consumption of raw vegetables increased likelihood of 
infection.  
 In contrast to Western studies, a study from Southern China failed to support 
the above finding as water being a source of infection. No association was found 
between drinking water and Helicobacter infection. Similarly studies from Korea 
and Bangladesh failed to support the above association.23 Sasaki et al. 
demonstrated presence of Helicobacter DNA in ponds and springs but not in 
potable water in Japan.24 
The opponents of the above environmental theory argue that two factors 
must be taken into account before interpreting the results of DNA detection in 
natural environment. One, the mere presence of the bacterial DNA does not 
indicate presence of viable bacteria and secondly, specificity of DNA PCR in the 
environments were yet to be discovered. When H.pylori is exposed to unsuitable or 
hostile conditions, it transforms into a non-culturable but viable coccoid form. 
  
However, recent studies have also questioned this hypothesis, claiming that these 
coccoid forms are non-viable and represent early stages of bacterial cell death.25 
EVIDENCE FOR GASTRO-ORAL TRANSMISSION 
 Refluxed gastric juice is considered as a most likely source of infection as 
upto 58% of infected subjects harbor the bacteria in their gastric juice. Also, there 
seems to be a higher prevalence of infection among gastroenterologists.26 Vomiting 
and regurgitation of food in children maybe an important factor contributing to 
children being the source of infection. Leung et al. postulated that transmission 
through vomitus is a possible mode of transmission.27 Parsonnet et al. conducted a 
study in which they were able to culture Helicobacter pylori from the vomitus of 
adult subjects after administering an emetic to induce vomiting. They were also 
able to culture the bacteria from air samples obtained 0.3 meters away from the 
subjects when they were vomiting. However samples taken 1.2 meters away failed 
to yield positive results.28 
EVIDENCE AGAINST GASTRO-ORAL TRANSMISSION 
 Numerous attempts at culturing Helicobacter from the oral cavity have 
failed. However, there are numerous studies in which the bacteria has been 
cultured from dental plaques. Desai et al. found the presence of Helicobacter pylori 
in the dental plaques of 98% of his test subjects, Indian dyspeptic patients. His 
  
study was based on Urease Breath Test only. The study was confounded because 
of the presence of other Urease producing bacteria as part of the normal oral flora. 
This could point towards the false relationship put forth by this study. One more 
possibility is that H.pylori could even be a part of the autochthonous microbiota.35 
Another consideration to be kept in mind is the absence of increased prevalence in 
dentists and dental workers who are constantly exposed.36 
EVIDENCE AGAINST FAECO-ORAL TRANSMISSION 
 Though fecal transmission of Helicobacter pylori has been elucidated, there 
exist certain factors that bring this postulate under question. This bacteria is not 
adapted for such passage. Infact, there is surmounting evidence that the bacteria is 
lethally affected by bile. Therefore survival of the bacteria after passage through 
the bowels is highly unlikely.37 But in patients who had received purgation prior to 
testing tested positive for culturability of H.pylori in the stools. The mere 
demonstration of the presence of Helicobacter pylori DNA in stools by PCR does 
not indicate presence of viable bacilli. 
As an inference , unlike hundreds of other infectious diseases that have been 
successfully prevented by epidemiological studies and preventive measures, the 
infection caused by Helicobacter pylori still proves to be an elusive adversary. 
  
Much deeper understanding of its epidemiological profile including modes of 
transmission are essential prior to any attempts at controlling the disease. 
FACTORS INFLUENCING TRANSMISSION 
 There are two major factors that influence the transmission of Helicobacter 
pylori. They are Socioeconomic status and Genetic predisposition. 
 Low Socioeconomic status is strongly associated with infection with the 
bacteria. An interesting aspect is that the socioeconomic status of the individual 
during childhood has a strong bearing on the acquisition of infection. Any 
individual who started at a lower strata has the same risk of infection even after 
migration to a higher socioeconomic status in adulthood. There is a higher 
prevalence of infection in economically backward groups settled in developed 
countries.29  In a study by Malaty et al. it was found that Blacks and Latin 
American people settled in USA still had a higher rate of infection prevalence 
compared to the native population inhabiting the same locality. They also showed 
that identical twins reared apart had high degree of discordance when tested for 
H.pylori status.30 
 The only setback with considering the socioeconomic status of an individual 
as a factor influencing transmission is that this criterion is very broad in the sense 
that there are numerous contributing factors that are encompassed within it. These 
  
include living conditions, population density and literacy. Higher the density, 
higher the chance of transmission. Siblings using the same room have increased 
prevalence.29 
Another interesting scenario is one in which British soldiers posted in areas 
with poor hygiene conditions for long periods didnot develop the infection. This 
further supports the hypothesis that the infection is primarily acquired during 
childhood.31  Forman et al. showed the existence of an inverse relationship between 
educational status and prevalence of H.pylori infection. 
 Interestingly, there has been a steady decline in the prevalence of infections 
in countries with evolving socioeconomic conditions like Japan. A similar trend is 
noted in Korea where there has been a gradual shift in living conditions. 
 The second factor influencing the transmission of bacteria is Genetic 
predisposition. High degree of concordance has been demonstrated in identical 
twins.32 
 
 
 
 
  
ANATOMY OF STOMACH 
The stomach, as a J-shaped dilatation of the gastrointestinal tract, located between 
the oesophagus and duodenum. It functions as a reservoir of  food and initiates 
digestion. Stomach volume ranges from about 30 mL in a neonate to 1.5 to 2L in 
adulthood. ( Fig . 6 ) 
 
EMBRYOLOGY ( Fig.10 ) 
The stomach develops in the fourth week of gestation as a dilatation of the distal 
foregut. As the stomach enlarges, the dorsal aspect grows rapidly than the ventral 
part, thus forming the greater curvature. During the development process, the 
stomach rotates 90 degrees along its longitudinal axis and thus the greater 
curvature comes to the left and the lesser curvature to the right. The combined 
effects of rotation and differential growth result in the stomach lying transversely. 
This also explain the innervation of the stomach: the right vagus nerve going 
posteriorly and the left one going anteriorly. 
 
GROSS ANATOMY 
The oesophago-gastric junction lies to the left of the 10th thoracic vertebra, 
1 to 2 cm below the diaphragmatic hiatus. The gastro duodenal junction lies at L1 
and generally to the right of the midline . Caudal part of the greater curvature may 
  
extend below the umbilicus when there is stomach dilatation caused by distal or 
outlet obstruction. The greater curvature comes to the left, the lesser curvature 
comes to the right. Posteriorly,  pancreas, transverse colon, diaphragm, spleen, and 
apex of the left kidney and adrenal gland form the stomach bed structures. The 
posterior wall of the stomach forms the anterior aspect of  lesser sac. Anteriorly, 
the liver binds the stomach. 
 
The stomach is completely covered by peritoneum, except for a small area at 
the gastro esophageal junction. This peritoneum has a double layer that passes 
from the lesser curvature to the liver as the lesser omentum and then hangs down 
from the fundus and greater curvature as the greater omentum, extending to the 
transverse colon as the gastrocolic ligament, spleen as the gastrosplenic ligament, 
and diaphragm as the gastrophrenic ligament. 
 
The stomach is divided into four anatomical regions.  They are the Cardia, 
Fundus, Body, Pyloric Antrum and the Pylorus. The cardia is that part of the 
stomach immediately adjacent to the junction with the esophagus. Controversy 
exists as to the nature, location, and extent of cardiac mucosa. The fundus projects 
superiorly. It is dome-shaped and is the most superior portion and is in contact 
above with the left part of the diaphragm. The body is the largest part of the 
  
stomach and is located below the fundus. The incisura angularis is a fixed, sharp 
indentation that marks the distal aspect of the body . The gastric antrum extends 
from its indistinct border with the body to the junction of the pylorus and the 
duodenum. These gross anatomic landmarks correspond roughly with the histology 
of the stomach. The antral mucosa in reality extends from an area on the lesser 
curvature somewhat above the incisura.  
 
The pylorus is a tubular structure that connects the duodenum to the stomach 
and contains the pyloric sphincter. The pylorus is mobile and is usually located       
2 cm to the right of midline at the level of  L1 vertebra. 
 
VASCULAR SUPPLY AND  LYMPHATIC DRAINAGE ( Fig.8 ) 
The arterial blood supply to the stomach is derived from branches of the 
celiac artery—Common Hepatic, Left Gastric artery and Splenic vessels —that 
form two arterial arcades along the greater and lesser curvatures. The lesser 
curvature is supplied from above by the Left Gastric artery, a direct branch of the 
Celiac Axis and from below by the Right Gastric Artery, a branch of the common 
Hepatic artery. The greater curvature below the fundus is supplied by the left 
Gastroepiploic artery,a branch of the Splenic artery and from below by the right 
Gastroepiploic artery,a branch of the Gastro duodenal artery. The right and left 
  
Gastroepiploic arteries usually terminate by completing the greater curvature 
arcade. The arterial supply to the fundus and proximal part of greater curvature is 
through the Short gastric vessels originating from the Splenic artery. 
 
The venous drainage of the stomach generally accompanies the arterial 
supply, emptying into the portal vein mostly. The left and right Gastric veins drain 
the lesser curvature of the stomach. The right and left Gastroepiploic veins drain 
the inferior aspect and a portion of the greater curvature. The right Gastroepiploic 
vein terminates in the Superior Mesenteric vein. There is no gastro duodenal vein. 
The Left Gastroepiploic vein becomes the Splenic vein and later receives the Short 
gastric veins.  
 
Most of the lymphatics goes to the celiac nodes. Lymphatic channels 
anastomose freely in the gastric wall, with lymphatic flow directed into one of four 
groups of nodes. The inferior gastric region drains into sub pyloric and omental 
nodes, then the hepatic nodes, and finally in the celiac nodes. Lymphatics from the 
superior aspect of the greater curvature initially drains into pancreatico splenic 
nodes and then to the celiac nodes. The lesser curvature region drains into the left 
and right gastric nodes accompanying their respective vessels and terminates in 
  
celiac nodes. The pyloric portion of the lesser curvature drains into the 
suprapyloric nodes, hepatic nodes then to the celiac nodes. 
 
GASTRIC INNERVATION 
The innervation of the stomach comes from both the sympathetic and 
parasympathetic nervous systems. The gastric sympathetic innervation arising 
predominantly from sixth to eighth thoracic spinal nerves whose postganglionic 
fibers course through the celiac plexus. Accompanying these are afferent pain-
transmitting fibers from the stomach and motor fibers to the pyloric sphincter. The 
parasympathetic innervation is via the vagus nerves, which form the distal 
esophageal plexus, which gives rise to the posterior and anterior trunks near the 
cardia. The trunks contain pre-ganglionic parasympathetic fibers, as well as 
afferent fibers from the viscera. These trunks give rise to celiac and hepatic 
branches before continuing on slightly to the right of the lesser curvature as the 
anterior and the posterior nerve of Latarjet. These nerves give rise to multiple 
gastric branches to the stomach wall, where the pre-ganglionic fibers synapse with 
the ganglion cells in the submucosal or Meissner's and Myenteric or Auerbach's 
intrinsic nerve plexuses. From these plexuses, postganglionic fibers are distributed 
to cells and glands and to motor components of the stomach. 
 
  
TISSUE LAYERS OF THE STOMACH ( Fig.7 ) 
The luminal surface of the gastric wall forms thick, longitudinally oriented 
rugae, which flatten with distention. Four layers make up the gastric wall: mucosa, 
submucosa, muscularis propria, and serosa. Mucosa lines the gastric lumen, 
appearing as a smooth, velvety, blood-filled 
 lining. The mucosa of the cardia, antrum, and pylorus is somewhat paler 
than that of the fundus and body. It is within the gastric mucosa that most of the 
functional secretory elements of the stomach are situated. The submucosa provides 
the dense connective tissue framework of collagen and elastin. Lymphocytes, 
plasma  cells, arterioles, venules, lymphatics, and the submucosal plexus are also 
contained within the submucosa. The third tissue layer is the muscularis propria 
which is a combination of three muscle layers oriented from within out is oblique, 
circular and longitudinal muscles. The inner oblique muscle fibers course over the 
gastric fundus, covering the anterior and posterior aspects of the stomach wall. The 
middle circular fibers encircle the body of the stomach, distally forming the pyloric 
sphincter. The outer longitudinal muscle fibers course mianly along the greater and 
lesser curvatures of the stomach. The outermost layer is the serosa which is 
nothing but a continuation of the visceral peritoneum. 
 
 
  
HISTOLOGY 
The gastric mucosal surface is composed of a single layer of columnar 
epithelial cells 20 to 40 mm in height. These surface mucous cells contain basally 
located nuclei, prominent Golgi apparatus and dense cytoplasm with apically dense 
mucin-containing membrane-bound granules. The cells secrete mucus in granules, 
which are released by the process of exocytosis or apical expulsion or cell 
exfoliation. The primary role of mucus, along with bicarbonate is protection of 
luminal integrity from “the elements”: acid, pepsin, ingested substances, and 
pathogens. Cellular renewal time for a gastric surface mucous cell is approximately 
3 days. There are numerous gastric pits which contain gastric glands. These are the 
source of various secretory products of the stomach. 
Secretions from glands are as follows ( Fig.9 ) 
• Mucus neck glands – They are located in neck of gastric glands.  Cuboidal 
with basal nucleus. They secrete mucus. 
• Parietal cells – triangular cells with eosinophilic cytoplasm. Located in neck 
and partially the isthmus of gastric pit. They secrete Hydrochloric acid and 
Intrinsic factor. 
• Chief cell – Located at base of gland . They secrete Pepsinogen 
• Enteroendocrine cell - part of APUD (neural crest origin) cells. They 
secrete gastric hormones like gastrin and motilin 
  
ANATOMY OF DUODENUM 
 
The duodenum is the first part of the small bowel . Duodenum is the principal site 
of iron absorption.The term duodenum takes origin a Latin word meaning "twelve 
fingers' breadth". 
The duodenum is 25–35cm long. It begins at the bulb and terminates at ligament of 
Treitz.  
GROSS ANATOMY 
Duodenum is divided into 4 parts. 
First part 
The first part begins as a continuation of the pylorus. From here it passes laterally 
to the right then superiorly and finally Posteriorly for a distance of about 2.5 
inches, directed inferiorly into superior duodenal flexure. It is intraperitoneal. 
Second part 
located at level of L3 vertebra and continues into the inferior duodenal flexure. 
The Duct of Wirsung and Common Bile Duct end in second part of the duodenum 
at the major duodenal papilla . The dilatation where the two ducts join and form a 
common channel before opening into the papilla is known as Ampulla of Vater. 
Proximal to the major duodenal papilla is the opening of the minor duodenal 
  
papilla which forms the opening of the Accessory Pancreatic duct of Santorini. The 
major duodenal papilla marks the junction of forgut and midgut. 
Third part 
The third part of the duodenum begins at the inferior duodenal flexure and crosses 
to the left. It overlies the right ureter, right gonadal vessels, Vena Cava and Aorta.  
Fourth part 
The fourth part passes to the left of the aorta. Then, it recurves forwards and 
terminates at the duodenojejunal flexure . The DJ or duodeno-jejunal flexure is 
surrounded by a peritoneal fold containing muscle fibres. This is known as 
the ligament of Treitz. 
 
BLOOD SUPPLY 
There are two major vessels supplying the duodenum, They are the Superior 
and Inferior Pancreaticoduodenal arteries. The former takes origin from 
Gastroduodenal artery. It is one of the terminal branches. The latter originates from 
Superior Mesenteric artery. These vessels are nestled within the space between the 
C-Loop of the duodenum and the head of the pancreas.They form an anastomosis. 
This route could form a site of collateral between foregut and midgut vasculature. 
  
The venous drainage of the duodenum follows the arteries. Ultimately these 
veins drain into the Portal Vein either directly or indirectly through 
the splenic or superior mesenteric vein. 
LYMPHATIC DRAINAGE 
The lymphatic vessels travel along with the vessels. The nodes are 
Pancraeticoduodenal, Mesenteric and Coelia nodes. First echelon nodes are the 
Pancreaticoduodenal and Superior Mesenteric. All lymphatics eventually terminate 
in the celiac nodes. 
MICROSCOPIC ANATOMY 
Duodenum contains the same 4 layers that are seen in the remainder of the 
small bowel--namely, the mucosa which is lined by columnar epithelium. Beneath 
the epithelial layer lies the lamina propria and muscularis mucosa.All these 3 
layers form the mucosa in entirety.  The submucosa, the muscularis propria (with 
inner circular and outer longitudinal layers), and the serosa form the remaining 
layers. The serosa is nothing but a visceral peritoneal reflection.It is present only 
along the anterior aspect of the duodenum. The posterior aspect is devoid of any 
serosal covering. The duodenal mucosa is characterized by the presence of 
Brunner’s glands, which secrete mucus. 
 
  
PHYSIOLOGY OF GASTRIC ACID SECRETION 
Gastric acid secretion happens in several steps. The secretion occurs in the 
parietal cells of the gastric glands. These produce Hydrochloric acid as well as 
Intrinsic factor needed for Vitamin B12 absorption. Parietal cells are also known as 
Oxyntic cells. The 3 major stimuli for secretion are Gastrin, Acetylcholine and 
Histamine. There are 3 major receptors for each of the above effectors. They are 
CCK receptor for Gastrin, M3 receptors for Acetylcholine and H2 receptors for 
Histamine. The three receptors are activated by binding of their stimulatory 
effector. These may be acting via. IP3-DAG Pathway or cAMP Pathway. Hence 
cAMP and Calcium form the second messengers in the mechanism of acid 
secretion by the parietal cells or oxyntic cells of the stomach. The final common 
pathway in secretion is the H/K ATPase pump system. This is present in the 
basolateral membrane of parietal cells. It is an active transport anti-porter system. 
The electrochemical gradient needed for its function is created by active transport 
of sodium ions into the canaliculi from the cytoplasm of parietal cells. In short, the 
H/K ATPase pump tries to maintain electrochemical neutrality by actively 
pumping out Hydrogen ions into the lumen of the stomach. Adenosine 
Triphosphate are the drive to keep this machinery running constantly. 
The peak amount of acid that is stomach is capable of producing is 
160mM.This amount of acidity is 3 million times higher than arterial blood. The 
  
lowest pH  that can be seen is 0.8.  However, the actual pH measurable in reality is 
1 to 3 only. 
There are several phases of acid secretion : 
1. The Basal phase: This is the acid produced during the resting stage . No food 
is present and no digestive process is taking place. 
2. The Cephalic phase: One-third of secretion takes place in this phase.It is 
brought about by psycho-somatic stimuli like thought of food, smell of food 
etc. It is vagally mediated through Gastrin. It can be abolished by vagotomy.  
3. The Gastric phase:  Nearly half of the secretion is here. Entry of food into 
the stomac produces Accomodation and Receptive Relaxation . This 
stimulates release of gastric juices both through vagus and through local GI 
hormones. Caffeine also stimulates parietal cells to secrete acid . 
4. The Intestinal phase: Final phase of secretion when chyme passes to the 
duodenum. Stimulated by acid content and by amino acids. 
Basal acid output (BAO) is usually less than 10 mEq/hour 
Gastric acid production is regulated by both the autonomic nervous 
system and several enteric or GI hormones. The parasympathetic nervous system, 
via the vagus nerve, and the hormone gastrin stimulate the parietal cell to produce 
gastric acid, both directly and indirectly, through histamine from enterochromaffin 
  
- like cells (ECL). Vasoactive intestinal peptide(VIP) inhibits acid secretion.One 
more hormone that has similar effect is Secretin.  
The production of acid is regulated by positive and negative 
feedback systems. Four types of cells are involved in this process. They are   
• Parietal cells 
• G cells 
• D cells 
• Enterochromaffin-like cells(ECL cells)  
Besides this, the endings of the vagus nerve and the intrinsic nerve plexuses also 
influence the secretion. 
Nerve endings in the stomach secrete two stimulatory  neurotransmitters namely 
 acetylcholine and gastrin-releasing peptide(GRP) . They act on parietal cells and 
also through the production of gastrin from G cells and histamine from ECL cells. 
Gastrin acts on parietal cells by stimulating production of histamine. 
Histamine is the positive regulator of acid secretion. Its release is stimulated by 
gastrin and acetylcholine and inhibited by somatostatin. 
 
 
  
PATHOPHYSIOLOGY OF H.PYLORI INFECTION 
Helicobacter pylori is a bacteria with trophism towards the gastrointestinal tract , in 
particular, the stomach and the duodenum. Schwartz’s dictum states “No acid-No 
ulcer”. This epithet summarizes the thinking concerning the pathogenesis of peptic 
ulcer . However the recent dictum is “No H.pylori – No ulcer”. 90% of duodenal 
ulcers and 70% of gastric ulcers are infected with Helicobacter pylori.90-100% of 
duodenal ulcers heal within 2 months of anti-secretory therapy. The damage to the 
stomach occurs due to a complex interaction between the organism and the host 
immune system.. It colonizes the mucosa and attaches to the epithelial surface. A 
myriad of mechanisms have been proposed as to how this ubiquitous bacilli cause 
the pathological changes with which they have been intimately linked to.  
• Direct mucosal damage due to adherence of the bacteria to the epithelial 
surfaces (Fig .2) 
• Liberation of Vacuolating cytotoxin Vac A which causes vacuole formation 
within the epithelial cells , thereby leading to cellular damage 
• Vac A causing a negative immunomodulatory effect causing suppression of 
local T cell induced immunological response leading to prolonged intense 
unopposed infection 
  
• Direct stimulation of release of endogenous host inflammatory mediators such 
as IL-1, IL-6, IL-7, IL-12 and TNF Alpha from the mucosa 
• Urease, produced by the bacteria , splits urea into ammonia in vivo. This 
ammonia confers local protection or so called buffer from the effects of gastric 
acids by causing alkalinization and also defers local attack by antibodies. 
• Bacterial phospholipase caused degradation of membrane bound phospholipids 
leading to epithelial injury. 
• Antral acidification causes stimulation of Gastrin secretion from antral G cells 
leading to hypergastrinemia and G cell proliferation.33 
 
The antrum is the predominant site of colonization in the stomach.(Fig .3) The 
pH on the surface of antral glands is well tolerated by the bacteria allowing 
survival and promoting growth. A subset of infected population develop 
“Antral-predominant gastritis” characterized by chronic inflammation of the 
pyloric antrum. These are the people prone to develop duodenal ulcers. With 
the administration of PPI’s , there is inhibition of H-K ATPase mechanism 
leading to decreased acidity of the antrum causing proximal migration of 
bacteria to corpus and fundus. This predisposes to intestinal metaplasia of the 
fundic mucosa leading to increased incidence of Proximal gastric 
adenocarcinoma.  
  
 A second subset of individuals are prone to develop the so called “Corpus-
predominant gastritis” the features of which overlap Type A Auto-Immune 
gastritis. It is these people with corpus predominant gastritis that are more 
prone to develop distal gastric adenocarcinoma.38  
Chronic Helicobacter pylori infection has been linked to many other enteric 
infections such as cholera. It still remains under inquiry as to why a co-evolved 
bacteria would be pathogenic to humans. It is hypothesizes that an originally 
harmless commensal , has over time, acquired virulence genes as part of its 
own evolution from the host and environment. There seems to be an abundance 
of such laterally acquired genes that per say have no known function but can 
be linked to inflammatory responses within the host. 
 
 
 
 
 
 
 
  
TABLES & CHARTS  
Analysis of Symptomatology ( Ref. Chart 1) 
 
 
 
 
 
 
 
Duration of symptoms (Ref.Chart 2) 
Duration of Symptoms No.of Cases 
<1 week 37 
<6 months 48 
6 -12 months 7 
>12 months 8 
 
 
 
Symptoms No.of Cases 
Pain Abdomen 57 
Epigastric Pain 14 
Vomiting 13 
Heartburn 6 
Loss of Appetite  6 
Mass Abdomen 2 
Hemetemesis 1 
Malena 1 
  
 
Seropositivity in Symptomatic cases ( Ref Chart 3) 
Serology No.Of Cases 
Seropositive 61 
Seronegative 39 
 
Sex Distribution among Seropositve Cases (Ref Chart 4) 
Seropositive No.Of Cases 
Male 29 
Female 32 
 
Age Distribution of Positive Cases ( Ref Chart 5) 
  
 
 
 
 
Age Group No.Of Cases 
18-30 14 
31-40 11 
41-50 13 
>50 23 
  
Over the counter medication (Ref Chart 6) 
Users 60 
Non Users 40 
 
Risk Factors ( Ref Chart 7) 
Prevalence of Helicobacter pylori ( Ref Chart 8) 
 
 
Smokers 13 
Alcohol Users 9 
Positive Negative 
Active or Healed Ulcer 29 4 
Perforation 22 15 
Carcinoma Stomach 6 4 
Non-Ulcer Dyspepsia 2 7 
Gastiritis 2 7 
Duodenitis 0 2 
  
OBSERVATIONS AND RESULTS 
Study Design : Descriptive Study 
Period : January 2011 – December 2012 
100 Patients , 50 male and 50 female who had symptoms of acid peptic disease or 
its sequelae or dyspepsia , who attended the outpatient Department of Government 
Rajaji Hospital, Madurai or those who had been admitted as inpatients in 
Government Rajaji Hospital, Madurai were selected at random and Serological 
Testing for IgG anti-Helicobacter pylori antibodies was done using a Instant View 
Qualitative Lateral Flow Immunochromatography Kit which is commercially 
available and also subjected to endoscopy whenever possible.  
Generalized abdominal pain was the most common complaint with which 
the patients presented ( 57%) followed by complaints of Epigastric Pain (14%). 
Hemetemesis and Malena were the least common presentation in our study.(1%) 
The duration of complaints in majority of the cases were for less than 6 
months(48%) followed by Less than a week (37%) Most of these acute 
presentations were from Ulcer Perforation which a well known sequlae of Peptic 
Ulcer Disease. 
  
 61 out of the 100 symptomatic cases tested positive for Helicobacter 
pylori. Among the symptomatic cases 52.4% were found to be female. 23 out of 
the 61 positive cases were above the age of 50 years (37.7%) followed by 14 out of 
61 cases in the age group of 18 to 30 years. Another interesting and also worrisome 
observation is the prolific use or overuse of over the counter anti-secretory 
medications by symptomatic cases. 60% of cases described use of such drugs. This 
sort of misuse causes symptomatic but no permanent cure and also interferes with 
H.pylori testing.  In our study, only 13 cases seemed to smoke and 9 alcohol 
users. However , no conclusions can be drawn based on this observation since this 
information is more than likely to be biased , with the patients unwilling to reveal 
their actual addictive habits in full extent. The following prevalence figures for 
Helicobacter pylori can be obtained from our study.  
Patients with Proven Ulcers      -        29/33          -  87.8% 
Patients with Perforation           -        22/37         -  59.5% 
Patients with Cancer Stomach   -          6/10         -    60% 
Patients with Non Ulcer Dyspepsia –     2/9         -    22% 
Patients with Gastritis                -           2/9          -   22% 
Patients with Duodenitis             -          0/9          -    Nil       
  
DIAGNOSIS OF HELICOBACTER PYLORI INFECTION 
The American College of Gastroenterology recommends testing for Helicobacter 
in the  following scenarios.34 
• Patients with active ulcer 
• A past history of documented peptic ulcer 
• Gastric MALToma 
• Patients who have undergone surgery for Early Gastric Cancer 
• People at risk of developing ulcers or stomach cancers  
Mayo Clinic screening criteria for Helicobacter pylori are as follows ( Fig.15 ) 
Specific testing should only be performed in symptomatic individuals. 
Asymptomatic colonization can occur and may cause confusion. 
• Active Ulcer Disease 
• Past history of Acid peptic disorder 
• MALT Lymphoma 
• Alarm features 
• Test and Treat 
• < 45 years old dyspeptic cases 
  
Alarm features include GI bleeding, anemia, weight loss, persistent vomiting. In 
such situations the patient should be directly submitted for endoscopy and 
evaluation.  
Widespread testing for H.pylori is not recommended because of the insufficient 
evidence in cost-benefit advantage in prevention of associated diseases, possibility 
of inducing antibiotic resistance and potential negative effect of eradication. 
Conditions where evidence is inconclusive for diagnosis and treatment of 
Helicobacter pylori are , 
• Investigated Non-Ulcer Dyspepsia 
• With NSAID use 
• Gastro-Esophageal Reflux Disease 
• Population at risk for gastric cancer 
• Inexplicable pallor in an elderly patient 
• Idiopathic Thrombocytopenic Purpura 
 
NSAID and H.PYLORI Eradication 
• Eradication does not prevent ulcer formation 
• Eradication does prevent ulcer bleeding complications to some extent 
  
• Ulcer recurrence and re-bleeding from ulcer are reduced 
• Patients on long-term low-dose aspirin therapy should be evaluated and 
treated if necessary to prevent complications 
Diagnostic tests can be broadly classified into  
• Invasive 
• Non- Invasive Tests 
The Tests commonly in use for detecting presence of Helicobacter pylori are , 
• Blood Test  
• Breath Test 
• Stool Test 
• Urine Test 
• Endoscopic Testing – Biopsy and microscopy ( Fig. 9 ) 
       Biopsy and Rapid Urease Test (CLO Test) 
       Biopsy and Culture 
SEROLOGICAL TESTING 
IgM levels increases in active infection. It appears within 21 days of exposure. IgA 
is more specific in children. However , overall IgM and IgA lack the sensitivity of 
IgG and hence have limited clinical value in screening. IgM is more useful to 
evaluate effectiveness of therapy. Screening for IgG has the best overall sensitivity 
  
and specificity. It is useful for mass screening purposes. The main advantage is that 
it can be held reliable even in cases taking PPI unlike most other tests. Samples can 
be easily obtained.  
Disadvantages are 
• it cannot be used to demonstrate eradication of infection. 
• False positive tests are common in low prevalence populations 
• Positive results should be confirmed by other modalities 
Bayes’ Theorem holds true in sero testing. It states that when the prevalence of a 
disease is low, the chances are that the diagnostic test will show false positives. 
Therefore serological testing has low positive predictive value in low prevalence 
populations. 
UREASE BREATH TEST 
The Urease Breath test is a rapid diagnostic test. It relies on the fact that 
urease present in H. pylori breaks down urea to ammonia and carbon dioxide. 
Urease breath tests are recommended as a preferred non-invasive test for 
detection and also for evaluation of H.pylori status after completion of treatment.56 
Patients swallow urea labeled with either radioactive carbon-14 or non-
radioactive carbon-13. 57 In the subsequent 30 minutes, the detection of 
  
radioactivity in the exhaled breath is indicative of presence of urea that was split; 
this indicates that the enzyme urease which is a characteristic feature of the 
bacteria Helicobacter is present in the stomach. 
As two types of urea are used, specialized equipment are needed for 
evaluation. C-14 is normally measured by scintillation and Carbon-13 by mass 
spectrometry. Samples are sent to a laboratory for analysis. Mass correlation 
spectrometry can be performed as an office test since breath samples are 
continuously collected, and results are provided immediately within minutes. 
Comparison between the values obtained before and after the test is done. 
This is compared to a cut-off value and results declared. The determination of the 
cut-off value requires usage of many different detection techniques.The value is 
chosen based on the best combination of sensitivity and specificity. 
The test detects active infection. Intake of acid suppression drugs such as 
PPI or antibiotics such as Amoxicillin causes error in results. Hence this test is 
useful only after 2 weeks of stoppage of drugs or 2 weeks after completion of 
treatment regimen. 
Some say that H.pylori in dental plaques interfere with results.57 
 
 
  
The disadvantages are 
• It is expensive 
• Specialized equipment are needed to assay the carbon dioxide analyte 
• Infrastructure is needed to safely handle radioactive materials 
 
ENDOSCOPY ( Fig 11 to 16 ) 
Endoscopy is an invasive investigation and is recommended in  
• asymptomatic individuals more than 45 years age  
• Any patient with alarm features.  
The specimen obtained by biopsy is stained with special stains. Some of them 
are 
• Gram stain 
• Giemsa Stain 
• Silver stain 
• Immonostains 
Endoscopy has more than 95% sensitivity and specificity. Multiple biopsies 
increases the accuracy of diagnosis. The disadvantage is that the procedure is 
  
invasive and costly and requires expertise to perform. Its sensitivity is affected 
in individuals taking anti-secretory therapy. 
RAPID UREASE TEST 
Also known as “CLO Test”. Endoscopy is performed and biopsies are taken. 
Samples are placed on reaction strip or agar gel containing Urea, Buffer and a pH 
indicator. The Urease present in the bacteria will breakdown the urea impregnated 
and will release ammonia that will cause the pH indicator to change colour. This 
indicates positive result. It is inexpensive and results have to be read within 3 
hours.Anti-secretory and antibiotic therapy will cause false negatives. Hence it is 
not recommended for those on therapy. 
CULTURE 
Culture is not routinely performed. It is useful only in cases of treatment failure to 
assess sensitivity and plan further treatment. 
Specific conditions required are 
• 5 to 7 days if culture plates are held at 37 degrees Celsius 
• 5 – 10% oxygen and 5-12% carbon dioxide with humidity 
• Brucella agar with 5% horse blood 
• Brain Heart infusion agar enriched using 7% horse blood – Most successful 
  
• Other media used include Chocolate agar, Mueller-Hinton agar, Wilkins 
Chalgren media. 
Colonies will be Urease , oxidase and catalase positive and Hippurate 
negative. The later will distinguish H.pylori from other enteric organisms. 
Non adherence to strict culture conditions will show grey translucent colonies with 
swarming. 
The reasons for negative culture may be as follows 
• Only one biopsy from each patient. Increasing the number of specimen from 
a single patient will improve the yield from the culture 
• Helicobacter is a slow-growing , fastidious organism and may not properly 
culture if conditions are not met. 
• Patient ingestion of anti secretory drugs can reduce viability of bacteria 
• Use of abundant gluteraldehyde solution to sterilize the endoscope may have 
deleterious effect on the organism. 
FECAL ANTIGEN TEST 
     This utilizes Enzyme immunoassay format. It uses multiple 
monoclonal antibodies to detect H.pylori. It is more accurate than serology in 
population with low pretest probability. Therapy caused altered results. Fecal 
  
antigen testing can be used 4 weeks after completion of therapy to assess 
effectiveness. It is an alternate to Urease Breath Test for this purpose.  
                     
 There are numerous other methods of diagnosis, though most are only of 
research value rather than actual diagnostic value. One such method is isolation 
from Dental plaques. Their presence in dental plaques can be explained by the fact 
that the area around the plaques has low redox potential and hence promotes the 
growth of facultative anaerobes. The bacteria normally present ferment 
carbohydrates in the food thereby producing low pH levels. This microaerophilic 
anaerobic environment is ideal for growth of Helicobacter pylori with the average 
oral temperature of 35 – 37 degrees Celsius.  
Blood testing and Breath test are often the first line investigatory modalities in 
common usage 
There are numerous modes of testing for Helicobacter pylori but none are 
foolproof.  
For Example, The urine ELISA which is not commonly used has a sensitivity of 
96% and specificity of 79%. 
 
  
The most reliable methods are 
• Endoscopic Biopsy and Rapid Urease Test 
• Histological Examination 
• Microbial Culture 
Cure of the disease can be confirmed by 
• Urease Breath Test 
• Fecal Antigen Test 
They should be performed after 4 weeks of completing treatment. Serology is 
not useful to assess success. If they are positive, patient should be subjected to 
Endoscopy, biopsy and sensitivity testing. 
 
CHOICE OF DETECTION METHODS BASED ON CLINICAL 
SITUATION 
New Onset Peptic Ulcer 
Patients diagnosed by radiograph or endoscopy should undergo Rapid Urease test 
or Serological Testing respectively. If found to be positive , the patient has to 
  
undergo an eradication regimen. If initial tests show negative, the result has to be 
confirmed by another test. 
If the confirmatory test is also negative, the patient is put on standard ulcer therapy 
with PPI or H2 Blockers. 
If the confirmatory test is positive , then the initial test is taken to be false negative 
and treatment instituted with an effective H.pylori regimen. 
 
History of Peptic Ulcer Disease 
Patients who are on anti-secretory medications may have documented disease or 
self reported disease. All these cases should undergo non-invasive diagnostic 
testing.  
If negative , anti-secretory therapy should be stopped. After 4 weeks of stoppage, 
the patient should undergo stool antigen or after 2 weeks should undergo Urease 
Breath Test.  
If found to be positive, therapy must be given. If still negative, no role of anti-
secretory or anti H pylori medications. Patients with objective evidence are more 
likely to have infection with Helicobacter. 
 
  
 
Dyspepsia 
Recent onset dyspepsia and younger than 50 years of age with no 
‘alarm’symptoms should undergo non-invasive testing. This may be Urease breath 
test or Serological testing. If found positive treatment is started.  
In patients with age more than 50 years and alarm features, direct endoscopy is too 
be performed. If ulcer is found , biopsy and Rapid Urease Test is done and if 
positive , therapy started. If negative, then serological test or histological 
examination of the biopsy specimen is indicated. 
 
 
 
 
 
 
 
 
  
 
TREATMENT OF HELICOBACTER PYLORI INFECTION 
“Eradication” is defined as “Negative test for 4 weeks or longer after completion of 
therapy” . Suppression of the bacteria may occur during therapy and hence failure 
to detect the bacteria within 4 weeks of therapy may give false-negative results. 
The therapeutics of Helicobacter pylori infection involves 3 step approach – 
Diagnose , Treat , Confirm Cure. The very location of the bacteria provides unique 
challenges in the treatment of infection. The drugs used for treatment need to 
penetrate the thick gastric mucous and also need to be highly active in a very low 
pH environment. In 1990’s monotherapy was advocated. However, emerging anti 
microbial resistance to single drug therapy led to the advent of multidrug 
combination anti microbial therapy. 
According to the Maastricht 2-2000 Consensus Report46 , eradication is strongly 
recommended in  
• All patients ulcer disease 
• In patients with low grade MALTomas 
• In individuals with atrophic gastritis 
• After gastric cancer resection 
• First degree relatives of patients diagnosed with cancer stomach 
  
 
The question of whether patients with functional dyspepsia, chronic NSAID 
therapy and individuals with GERD should be treated remains under debate. 
However, individuals with H.pylori positive non-ulcer dyspepsia and those with 
corpus-predominant gastritis should undergo eradication. These individuals are 
more susceptible to develop gastric adenocarcinoma than those with antral-
predominant disease. Hence patients with non ulcer dyspepsia showing corpus-
predominant gastritis should always undergo a regimen to eradicate infection.47 
Eradication of Helicobacter pylori in chronic NSAID users has been shown 
to reduce the incidence of developing peptic ulcer.48 
90-100% of duodenal ulcers heal within 8 weeks of anti-secretory therapy. 
Anti-secretory drugs donot change the natural history of the disease. They provide 
only symptomatic aid and delay the development of complications. Only the 
eradication of H.pylori can alter the natural history of the disease. Eradication 
decreased the incidence of ulcers and ulcer recurrence.55 It also prevents rebleeding 
from ulcers and normalizes the histology and acid secretion in chronic 
gastritis.Earlier clinicians believed in 6 week therapy. However, current consensus 
suggests 2 weeks therapy is sufficient. 
 
  
 
MARKOV MODEL 
o All patients with dyspepsia were enrolled 
o Patients should not have any alarm features like bleeding or weight loss 
o Any patient tested positive for H.pylori received triple drug therapy 
o If no relief or symptoms recur, patient should undergo endoscopy and 
biopsy.  
This model aims at reflecting the ‘typical’ approach to dyspepsia 
management. 
DRUGS USED IN TREATMENT 
The drugs currently used in the armamentarium against Helicobacter pylori are 
• Proton Pump Inhibitors (PPI) 
• Bismuth Salts 
• Metronidazole 
• Clarithromycin 
• Amoxicillin 
• Tetracyclines 
 
  
 
PROTON PUMP INHIBITORS 
PPI’s have a direct anti-microbial effect against Helicobacter pylori invitro. 
However , in the invivo setting this effect seems to be of little actual value in 
eradication of infection. 
Mechanism of action 
Proton pump inhibitors act by irreversible inhibition of H+/K+ ATPase pump 
found in the acid secreting cells.This pump forms the final effector system and 
hence is the best target to be knocked off. 
The reason for PPI being much more effective than H2 Blockers are 
• Targeting the terminal step in acid production 
• Irreversible inhibition of the H+/ K+ ATPase pump 
They suppress acid secretion by up to 99%.  
The elevated pH in the stomach will hasten the healing of duodenal ulcers. 
The drawback of this decrease in Hydrochloric acid is that the normal amount of 
HCl  required for protein metabolism and Vitamin absorption is not available. 
The proton pump inhibitors are given in an inactive form. This inactive form 
is lipophilic and easily crosses into parietal cell canaliculus that have acidic 
  
environments. In an acid environment, the inactive drug is activated by a process 
known as protonation and is converted into its active form. It is this active form 
that will covalently and irreversibly bind to the gastric proton pump and cause 
inhibition. 
Pharmacokinetics 
The absorption and bioavailability are suppressed by concurrent food intake. 
However, there seems to be no proven reports of this phenomenon affecting the 
efficacy or bio-availability of the drug.  
The t1/2 of proton pump inhibitors is ½ to 2 hours but a statum dose can last 
for upto 3days as the drug is accumulated in the oxyntic cells and also recovery of 
H/K ATPase pump takes long time.59 
These drugs  
• Decrease gastric acidity and thus prevent  degradation of the drugs in 
the stomach 
• Decrease gastric juice volume 
• Decrease washout of the drugs and enhances luminal antibiotic 
concentration 
 
 
  
 
BISMUTH 
Bismuth is one of the first agents used against H.pylori. It is directly 
bactericidal. Bismuth subsalicylate - chemical formula of C7H5BiO4, is 
a colloidal substance. Its chemical structure is yet to be fully delineated. An 
empirical structure Bi38O44{C6H3(OH)CO2}26 has been recently put forth. Its 
Minimum Inhibitory Concentration (MIC) is high.  
Mechanism of action  
 Inflammed tissues are coated and it prevents exudation of fluid from them 
 It promotes absorption of fluid secreted into the lumen 
 Inhibition of synthesis of inflammatory mediators such as Prostaglandins 
 Reduces gastric motility 
 Buffering of bacterial toxins 
 Direct bactericidal effect of salicylic acid 
 ‘Oligodynamic’Effect – Bismuth heavy metal in non-toxic doses has anti   
 bacterial action 
 Weak antacid properties 
Children should not take medication with bismuth subsalicylate while 
recovering from influenza or chicken pox, as evidence points to an association 
  
between the use of salicylate-containing drugs during active infection and 
convalescent period and the onset of Reye's syndrome. For the same reason, it is 
recommended that nursing mothers not use medication containing bismuth 
subsalicylate because small amounts of the medication are secreted in breast milk 
and pose a chance of Reye's syndrome to nursing children.60 
METRONIDAZOLE 
It is a very effective drug. It is actively secreted into the gastric juice and 
saliva. Its action is pH independent. It is ingested as a pro-drug that is activated by 
bacterial nitroreductase. The mechanism of action is it causes loss of helical 
structure of bacterial DNA, strand breakage and hence impairment of bacterial 
function. 
Metronidazole, taken up by diffusion, is selectively absorbed by anaerobic 
bacteria and sensitive protozoa. Once taken up by anaerobes, it reacts non-
enzymatically with reduced ferredoxin, which is generated by pyruvate oxido-
reductase. Many of the reduced nitroso intermediates will form sulfinamides and 
thioether linkages with cysteine-bearing enzymes, thereby deactivating these 
critical enzymes. As many as 150 separate enzymes are affected. 
Also, the Metronidazole metabolites are taken up into bacterial DNA, and 
form unstable molecules. This function only occurs when Metronidazole is 
  
partially reduced, and because this reduction usually happens only in anaerobic 
cells, it has relatively little effect upon human cells or aerobic bacteria.61 
Though there has been an increase in bacterial resistance, this can be 
overcome by increasing the dosage. 
CLARITHROMYCIN 
It is a macrolide antibiotic,  a derivative of Erythromycin. However, the former is 
more acid-stable and has consistent absorption characteristics than the latter. 
Mechanism of action 
Clarithromycin binds to the subunit 50S of  bacterial ribosome and inhibits the 
translation of peptides. Besides this bacteriostatic effect, clarithromycin also has 
bactericidal effect on certain strains. It has a longer elimination half life compared 
to Erythromycin. 90% of H.pylori eradication regimen use Clarithromycin.  
Pharmacokinetics 
Clarithromycin is acid resistant and hence orally consumable. It attains high 
concentration in phagocytes.This enables its transport to the site of infection. 
During active phagocytosis, large concentrations of clarithromycin are released, as 
much as 10 times than blood concentration. Peak concentrations were found in 
hepatocytes and lungs. 
  
Metabolism 
Clarithromycin shows rapid first-pass metabolism. However, 14-hydroxy 
Clarithromycin is twice as active and has a longer half-life of seven hours as 
against five hours for Clarithromycin. Elimination is primarily by urine and bile. It 
has the best bioavailability at 50%. 
Side Effects 
Its most common side effects are nausea, abdominal pain . Other side effects 
include irritability, headaches, rashes, parosmia, dysguesia  including a metallic 
taste. Anxiety attacks and nightmares may be seen. More serious side effects are 
cirrhosis and acute renal failure.  Chest pain, palpitations and rhythm disturbances 
have also been documented. 
An interesting finding is that Clarithromycin causes positive results on urine 
drug screens for cocaine.It can very rarely cause organic psychosis.62 
When taken along with some statins, myalgia may occur. A risk of oral 
candidiasis, due to the elimination of oral microbial flora is also known to occur. 
 
 
 
  
Resistance 
Resistance cannot be surmounted by increasing the dosage of the drug. 
Development of resistance is mostly through receipt of the erm(B) gene. This gene 
also causes development of resistance to all macrolide group of antibiotics.63 
Contraindications 
• Not to be used in Hepatic or Renal insufficiency 
• Individuals with cardiac problems like arrhythmias64 
• Pregnancy 
• HIV patients as florid interaction with Retro viral drugs is 
documented 
• Epileptics on Carbamazepine (CBZ) . Metabolism is inhibited leading 
to accumulation and extra-pyramidal side effects 
AMOXICILLIN 
It is related to Ampicillin. It is a Beta-Lactam antibiotic. 
Mechanism of action 
β-Lactam antibiotics are bactericidal, and act by inhibiting the synthesis of 
the peptidoglycan layer of bacterial cellwall. The peptidoglycan layer is important 
  
for cell wall structural integrity, especially in positive organisms, being the 
outermost and primary component of the wall. The final transpeptidation step in 
the synthesis of the peptidoglycan is facilitated by transpeptidases known 
as penicillin-binding proteins (PBPs). PBPs vary in their affinity for binding 
penicillin or other β-lactam antibiotics. The amount of PBPs varies among 
bacterial species. 
The β-lactam nucleus of the drug irreversibly binds to Serine residue of the 
PBP active site. This prevents the final cross linking of the peptidoglycan and 
interferes with bacterial cellwall synthesis.65 
 This drug is efficacious but providing gastric anti-secretory co-therapy is 
required. 
TETRACYCLINES 
These are polycyclic naphthacenecarboxamides. They act at the bacterial ribosome 
and prevent protein synthesis leading to production of non-functional proteins. 
They enter into the bacteria by two mechanisms – Passive diffusion through outer 
membrane hydrophilic pores. The second process is by an energy-dependent active 
transport system that pumps the drug through the inner cytosolic membrane. Once 
inside the cell, they attach to 30s subunit of bacterial ribosome and prevent 
aminoacyl tRNA access to the acceptor sites causing premature chain termination. 
  
Human cells do not contain 30s Ribosome subunits and hence these group of drugs 
do not affect normal human cells. 
 
CANADIAN HELICOBACTER STUDY GROUP 
TREATMENT RECOMMENDATION 
• All Helicobacter positive patients with gastric or duodenal ulcers , whether 
symptomatic or asymptomatic, should receive eradication treatment. 
• All H.pylori positive patients with MALToma must receive eradication 
treatment. 
RECOMMENDED THERAPY 
• Clarithromycin 500mg bd + Amoxicillin 1000mg bd + PPI bd  for 7 days 
• Clarithromycin 500mg bid  + Metronidazole 500mg bid + PPI for 7 days 
ENDORSED THERAPY 
• Amoxicillin 1000mg bid + Metronidazole 500mg bid + PPI bid for 7 days 
• Tetracycline 500mg qid + Metronidazole 250mg qid + Bismuth 
subsalicylate 2 qid for 14 days 
 
  
FOR TREATMENT FAILURE WITH FIRST LINE METRONIDAZOLE 
• Clarithromycin 500mg bid + Amoxicillin 1000mg bid + PPI bd for 7 -14 
days 
• PPI bid + Bismuth 2 q6h + Metronidazole 500mg q6h + Tetracycline 500mg 
q6h for 2 weeks 
FOR TREATMENT FAILURE WITH AMOXICILLIN AS FIRST LINE 
• Metronidazole 500mg bd + Clarithromycin 500mg bd + PPI bd for 2weeks 
• Bismuth subsalicylate 2 q6h + Metronidazole 500mg bd + Tetracycline 
500mg qid + PPI bid for 2weeks 
REGIMEN CURRENTLY USED 
• First line therapy -  triple therapy using  
o PPI bd + Clarithromycin 500mg bd + Amoxicillin 1g bd for 7 
days. 
• Second line therapy includes quadruple therapy based on  
o PPI + Bismuth salt qid +  Metronidazole 500mg tds  
+  Tetracycline 500mg qid for 2weeks 
  
  
Another second line therapy has been put forth which is claimed to be better 
than the standard quadruple therapy second line management 
o Rabeprazole 20mg bd + Amoxicillin 1000mg bd + Levofloxacin 
500mg od for 10 days. 
Rescue regimen after failure of initial treatment extends for 14 days. It 
includes, 
• RIFABUTIN 150mg bd  + LEVOFLOXACIN 500mg OD +  
AMOXICILLIN 1000mg bd  +  PPI bd for 14 days 
 
• RIFABUTIN 150mg bd + Ciprofloxacin 500mg bd + Amoxicillin 
1000mg bd + PPI bd 
 
• Tetracycline 500mg qid + Furazolidone 200mg bd + Bismuth 
subcitrate 120mg qid + PPI bd 
 
 
 
  
 The standard dose of PPI in all above regimen signifies the following dose twice a 
day 
• Esomeprazole 40mg  
• Omeprazole 20mg 
• Lansaprazole 30mg 
• Pantoprazole 40 mg 
• Rabeprazole 20mg 
OTHER REGIMEN 
There are certain parallel concept on treatment of H.pylori. A few are discussed 
here. 
• Sequential Therapy  
o PPI + Amoxicillin followed by PPI + Clarithromycin + 
Metronidazole – 5 days course of each set 
• Concomitant Therapy 
o All 4 drugs are administered together. It is less complex  
• Extended Sequential Therapy  
 continued for 14 days i.e. 7 days plus 7 days instead of 5+5 
 
 
  
• Sequential Concomitant Hybrid Therapy  
Extended Sequential Therapy + Continuing Amoxicillin for the entire 14 
days duration. 
• Under study 
Four times daily administration of three capsules containing  
420 mg Bismuth subcitrate + 375mg Metronidazole + 375mg 
Tetracycline and also 20mg Omeprazole twice daily for 10 days. 
• In Metronidazole resistant H.pylori , the following regimen shows >92% 
success rate.  
o Tetracycline 500mg qid + Metronidazole 500mg tds + Omeprazole 
20mg bid + Bismuth subsalicylate 2 tablets qid 
• A newer 4 drug regimen for H.pylori eradication is under trial in Western 
countries. These are the LOAD and LAC regimen 
LOAD Regimen 
Levofloxacin 250mg in the morning 
Omeprazole 40mg on an empty stomach 
Nitazoxanide 500mg bd with food 
Doxycycline 100mg at night 
  
LAC Regimen 
  Lansaprazole 30mg before breakfast 
  Amoxicillin 1000mg bd with meals 
  Clarithromycin 500mg bd with meals 
SIDE EFFECTS OF DRUGS 
PPIs Headache, Diarrhoea 
Clarithromycin GI upset, Diarrhoea, Dysgeusia 
Amoxicillin GI upset, Diarrhoea, Headache 
Metronidazole Metallic taste, Dyspepsia, Disulfiram like reaction 
Tetracycline GI upset, Photosensitivity 
Bismuth subcitrate Darkening of tongue and stools 
Furazolidone Nausea, Headache, Malaise, Hypersensitivity, Hemolytic 
anemia, disulfiram like reaction 
Rifabutin Red discolouration of urine, Rash, Diarrhoea, Vomiting, 
Ocular and Myelotoxicity 
Levofloxacin QT Prolongation, Seizures, Glucose intolerance 
 
 
  
KEY ASPECTS 
An “optimal therapeutic regimen” should produce >95% success rate in patients 
infected with susceptible strains. In cases infected with strains that are resistant , a 
cure rate of >85% is necessary. 
The logic behind twice daily administration of PPI is that the use of bismuth alone 
or once daily dose of PPI raises intragastric pH to around 4 – 5. This causes many 
bacteria to remain quiescent. For more effective eradication , more profound 
elevation of pH is essential . Hence bid dose of PPI is much more quintessential to 
eradication. However, in countries like Japan, where the people metabolize PPI 
slowly, there remains a prolonged effect even after once daily administration. 
Eradication can be achieved even by dual therapy with Amoxicillin and PPI.58  
• An adequate strategy is to apply two therapies to ensure 100% cure 
• Repeating the same course is not recommended 
• First choice should never include both Clarithromycin and Metronidazole 
• If PPI are not tolerated, they can be replaced by H2 Blockers 
• Use of Rabeprazole may be beneficial compared to Omeprazole because of 
heterogeneity in enzymatic activity73 
  
• Nonspecific drug reactions are liable to be misplaced as penicillin allergy. 
Hence investigation to rule out are essential. Patient should not be deprived 
of the effective penicillin therapy 
• Prolonged treatment for 2 weeks is ideal 
• Assessment of antibiotic sensitivity is needed to prevent resistance 
Though combining Clarithromycin and Metronidazole is highly effective, the 
problem occurs in cases of treatment failure. The bacteria will develop double 
resistance against both agents and further empirical therapy and regimen selection 
would become impossible.50 
ANTIMICROBIAL RESISTANCE 
Resistance can be primary – prior to initiation of therapy or secondary following 
failure of therapy. Resistance to Tetracycline and Amoxicillin are extremely rare.51 
The prime concern is with resistance to nitroimidazole groups like Metronidazole 
and macrolides like Clarithromycin. An interesting observation is that increasing 
the dose of Metronidazole from 1.0 to 1.5 mg/kg overcomes this resistance. 
However , Clarithromycin enjoys no such benefit. Resistance once formed leads to 
complete loss of effect irrespective of dosage. 
 
  
TREATMENT FAILURE 
Anti-microbial therapy often fails to eradicate the bacteria because of presence in 
certain sanctuary sites. This includes the oral cavity. The drugs act only at the level 
of stomach. The mechanism by which the organism harbours at the sanctuary sites 
still remains to be debated. However, one possible explanation would be that the 
bacteria is refluxed up from the stomach and gets lodged in dental plaques, which 
form the normal oral biofilm of the host.54 
FOLLOW UP 
Duodenal ulcers recur in only 6 % of cured patients in contrast to 67% in positive 
cases. 
Gastric ulcers recur in only 4% as against 59% in positive cases. Relief of 
symptoms alone cannot be taken as a sign of cure. Persistence of ulcer related 
symptoms may indicate persistence of infection. 66,67 However, continued 
symptoms too does not always indicate treatment failure. Therefore , follow-up 
with a confirmatory test to evaluate eradication of Helicobacter, irrespective of 
presence or absence of dyspeptic symptoms is always necessary. Non-Endoscopic 
testing is preferred if  confirmation is sought. 
  
Serology is not useful in the immediate post-treatment period due to high titre of 
antibodies in circulation. 68 After more than a year , seroconversion can be taken as 
a reliable confirmatory indicator of eradication. 69 
 
PERSISTANT INFECTION AFTER TREATMENT 
• Patient compliance to eradication therapy has to be assessed 
• Confirmation to presence of infection must be sought by either a non-
invasive test preferably, or by invasive modalities. 
• If found positive, second line eradication therapy has to be given 
• If persistent even after second line management, antibiotic susceptibility has 
to be assessed and appropriate drugs given. 
 
 
 
 
 
 
  
DISCUSSION 
Numerous studies have been a forerunner to ours in elucidating various 
aspects of disease caused by Helicobacter pylori infection. Each one has analysed 
particular aspects of the natural history of the infection and given varying 
conclusions.  
Javed et al. in 2010 have demonstrated an overall prevalence of around 80% 
in Peptic ulcer patients . They have also reported that epigastric pain being the 
most common symptom.  The same study group has also showed maximum 
prevalence of infection in the age group of 48 years to 55 years. Similarly, Sasoon 
Levi et al. in 1989 have demonstrated a prevalence of 86.27% and Querseshi et al. 
in 1997 have shown 92% prevalence.76  Our present study has shown similar results 
with the prevalence being perched at around 87.8%. 
Gisbert at al, have demonstrated a prevalence of 60% in perforated peptic 
ulcers as against close to 90% in uncomplicated peptic ulcer disease. 79 Both the 
above statistical observations are consistent with the figures derived from this 
study also.  
Obata et al. have evaluated the diagnostic accuracy of serological tests 
against the ‘gold standard’ tests and have reported sensitivity in the range of 87.5% 
  
to 95.5% and specificity in the range of 84.8% to 92.3%.77  The kit used in this 
study carries with it values of sensitivity 95.1% and specificity 94.1%.  
One of the commonly used test for Helicobacter pylori in the Urease Breath 
Test(UBT) . According to Miwa et al. UBT has sensitivity of 96.7% and specificity 
of 96.5%. 78  The serological kits used in our study has shown to carry comparable 
results. 
Thijs JC et al.80 have conducted a multi-center comparative study on various 
tests used to detect Helicobacter pylori. The observations from this study are as 
follows. 
TEST SENSITIVITY SPECIFICITY 
Culture 98.4 100 
PCR 96.7 100 
Microscopy 96 98.8 
Rapid Urease 90.2 100 
Urease Breath Test 100 100 
Serology 98.4 88.4 
Our Study 95.1 94.1 
  
Helicobacter pylori is a omnipresent bacteria that has been linked to 
numerous gastrointestinal diseases which include duodenal ulcer, gastric ulcer, 
gastric cancer, MALT Lymphoma, Non Ulcer dyspepsia and other Extra 
Gastrointestinal diseases like Idiopathic Thrombocytopenic Purpura etc. Half a 
million people die around the world from Gastric cancer making it the third largest 
killer of human beings.Inspite of the well elucidated ill effects of the bacteria , 
there are numerous opponents that argue against the case of eradication of 
Helicobacter pylori.  
The relationship between H.pylori infection and human host is proving to be 
complex. Risk posed by infection may involve differences in host susceptibility 
and virulence of the infecting strain.The strongest indication for eradication is 
duodenal ulcer . Marshall et al. has shown healing rates of upto 92% in treatment 
group and a much lower 12 month relapse rate.44 Also in cases of Non-Ulcer 
dyspepsia, eradication provided symptomatic relief in upto 81% of cases and relief 
lasts for 12 weeks.45 
The opponents of eradication argue that the environment in India is 
contaminated and GI infections are very common. Secondly, the widespread 
misuse of antibiotics has lead to widespread drug resistance. In numerous fixed 
dose combinations available in India, most have a sub-optimal dose of 
Amoxicillin. It is believed that the reinfection rate in India is around 60%. 
  
Helicobacter pylori is an organism well adept to humans with persistent 
infection and low level disease. This behavior tends to point to the speculation that 
Helicobacter pylori is a commensal rather than a pathogen. It is highly likely that 
most in the community have avirulent strains of the  bacteria that do not actually 
warrant eradication measures but also increases the possibility that eradication of 
such strains could be detrimental to health by abolishing H pylori induced gastric 
hyperacidity, destroying the natural barrier and leading to Gastrointestinal 
infections. Also it is believed to be a part of the body’s own innate immune system. 
H.pylori infection may even prevent allergic and autoimmune diseases in humans. 
The precise relationship between H.pylori and complicated ulcer remains to 
be established beyond doubt. Recurrent  ulcers after peptic ulcer perforation occurs 
mainly in H.pylori positive individuals. All patients with perforated peptic ulcer 
should undergo simple closure of perforation followed by eradication of the 
bacteria. Disappearance of the organism prevents, or atleast decreases ulcer 
recurrence and ulcer perforation in the future. Therapy has to be ideally started in 
the immediate post-operative period. In current context, the only indication for 
elective definitive surgical treatment for peptic ulcer disease is patients with 
intractable symptoms even after adequate eradication attempts , who are H.pylori 
negative. 
  
It has been shown that curing H.pylori infection may provoke reflux 
oesophagitis. It has been suggested that H.pylori infection enhances the ability of 
PPI’s to suppress gastric acidity. Therefore H.pylori positive oesophagitis patients 
heal faster than those who are negative. Rebound hyperacidity occurs in H.pylori 
negative patients on stopping PPIs.49 
The fact that though India has a much higher prevalence of H.pylori 
infection , there is a relatively lower risk of Gastric carcinoma. This paradox can 
be explained by the presence or absence of the more biologically active variant of 
CagA. The presence of less active form of the gene could explain the negligible 
incidence of gastric carcinoma in India. 
Coming to the Serological testing aspects of Helicobacter pylori, several 
studies have shown that kits made in the Western countries have a far less 
diagnostic accuracy than those manufactured in the East. The Use of local antigen 
in manufacture of serology kits aids to improve the accuracy of results specific to 
that population.70 
The identification of Helicobacter pylori infection in children with chronic 
abdominal pain is essential. However, the apt diagnostic method to be used is still 
under debate. Clearly it carries no advantage in subjecting children to invasive 
testing. However , use of serological testing in children needs to be validated. 
  
Results are not reliable in the pediatric age group. An possible explanation to this 
paradox is that the child’s immune response varies greatly compared to that of the 
adult population. The second explanation would be the lack of standardization and 
validation of commercially available assays with serum samples from infected and 
uninfected pediatric cases.71 
Furthermore, the detection of IgG antibodies in the saliva and Urease Breath 
Test in children need to be performed and substantially validated. 72 
In adults, serological testing has got comparable results with other means 
such as ELISA. The higher the antibody titre, stronger will be the band that 
appears in Test line. If a faint band is considered seronegative, it decreases 
sensitivity whereas increases the specificity. Screening of dyspeptic individuals 
with serology prior to endoscopy reduces the endoscopy workload by almost 
23.3% and only 3% of ulcers would be missed by doing so.74 
Smoking has been proven as a major risk factor in modulating individual 
susceptibility to infection with Helicobacter pylori. Cessation of smoking prevents 
progression of disease. The prevalence of virulent strains of H.pylori is more 
among smokers than non-smokers. Smoking causes increased expression of cag 
genes. This predisposes to higher chances of malignant transformation of gastric 
mucosal cells.75 
  
 As no major improvements have come since the advent of the original 
antibiotics against H.pylori, it still remains that only optimization of therapeutic 
regimens may be useful at present. Probiotics may exert a favourable effect during 
therapy. Also , addition of bovine lactoferrin has been shown to increase efficacy. 
But human recombinant lactoferrin has not shown to offer any such advantage.52   
There are numerous studies underway to explore the possibility of 
preventing Helicobacter pylori infection. The need for prevention arises from the 
rapidly growing antimicrobial resistance to the drugs used in treatment. Extensive 
vaccine studies have proven successful in mouse. 40 A number of foods are also 
believed to prevent infection. These include Green Tea, Red Wine, Broccoli 
sprouts, Garlic, Flavanoids and probiotics.41  Supplementing food with 
Lactobacillus containing or Bifidobacter containing yoghurt improves rate of 
eradication.42 Broccoli sprouts have a substance known as sulphoraphane that 
inhibits the bacteria.43  
The isolation of Helicobacter from dental plaques is a well known entity but 
whether the removal of plaques causes any change in recurrence rate still remains 
under study. Due to limited availability of effective drugs, the ideal modus to treat 
would be to establish sensitivity prior to initiating treatment. The major obstacle to 
this is the invasive nature and cost factors prima facia involved in Upper GI 
Endoscopy and biopsy. Precise identification of virulent strains of H.pylori and 
  
aggressive targeted eradication of only the virulent strains seems to be the 
optimum path to undertake. The possibility of the bacteria finding sanctuary in oral 
cavity and possibly causing recurrence needs to be explored and controlled. 
Eradication of Helicobacter present in the oral cavity requires precise identification 
of the oral bacterial ecological niche.  Future developments in polymerase chain 
reaction and serology testing to detect Helicobacter pylori will aid in providing 
insight into oral H.pylori and open further possibilities for non-invasive testing and 
steps to prevent recurrence. 
Helicobacter pylori is believed to be associated with other systemic and 
auto-immune diseases. To list out a few would be 
• Chronic Urticaria 
• Rosacea 
• Psoriasis 
• Sjogren Syndrome 
• Henoch Schonlein Purpura 
• Alopecia Areata 
• Systemic Sclerosis 
• Atopic Dermatitis 
• Behcet Disease 
  
• Generalized pruritus 
• Immune Thrombocytopenic Purpura 
• Lichen Planus 
• Aphthous Ulcers 
• Cholangiocarcinoma 
• Hepatocellular Carcinoma 
• Gallstone formation 
• Inflammatory Bowel Disease 
• Sideropenic Anemia 
 
Helicobacter pylori increases permeability of stomach lining and thus 
increases exposure to allergens in the gastro-intestinal tract. This is a plausible 
explanation for association with Urticaria, Atopic Dermatitis and Generalized 
Pruritus. Also, there seems to be increased levels of nitric oxide in the blood 
leading to flushing and erythema of Rosacea. It triggers autoimmune reactions in 
skin and glands causing Sjogren Syndrome and Psoriasis. 
 
In 1994, The International Agency for research on Cancer classified 
Helicobacter pylori as a ‘Carcinogen’. The risk of non-cardia gastric cancer is 6-8 
  
folds higher in H.pylori infected individuals than those who are uninfected.  
Eradication leads to a moderate decrease in the risk of gastric cancers and also less 
worsening of pre-cancerous lesions. The organism is also linked to a rare type of 
Non-Hodgkin’s B cell type Lymphoma arising from Mucosa Associated Lymphoid 
tissue called as MALT Lymphoma or simply MALTOMA. The stomach lining in 
reality lacks lymphoid tissue. It is because of the chronic inflammation produced 
by the Helicobacter that stomach acquires lymphoid tissue and MALTOMA arises 
from such tissue. 
There seems to be an inverse relation between Helicobacter pylori and 
gastric cardia cancer. In the West, the effective eradication of H.pylori has 
paralleled the increases incidence of cardia cancers. This may be due to the 
decreases acidity in the stomach secondary to chronic gastritis leading to atrophy 
of the gastric glands. This causes reduced reflux into the esophagus . 
Inspite of high incidence of infection in the Indian population, there seems to 
be a surprisingly low occurrence of sequlae of infection such as gastric 
adenocarcinoma.. Biological co-ordinates of such ‘protection’ needs to be studied 
with the aid of genome sequence of the bacteria. This type of research is feasible in 
the not too distant future as genomic study is becoming far and more affordable as 
years go by. The most widespread debate about this organism is whether it is  a 
parasite, commensal or mutualist. There are certain evidences showing the bacteria 
  
to be preventive in cases of mainly childhood enteric infections such as diarrhea 
and also in cases of GERD , Esophageal cancer and Asthma. Eradication of the 
bacteria can lead to increased occurrence of such diseases. In this context, 
Helicobacter pylori , with its aggressive eradication drive in the west can be 
classified as an ‘endangered species’. It is considered that per-historic versions of 
the bacteria may be considered as ‘human parasites’ prior to acquiring virulence 
factors. The present day Helicobacter can be dubbed as a ‘Commensal’ only after 
its ‘disarmament’ meaning its virulence mechanism makes it a ‘classical pathogen’ 
. 
 
H.pylori has also been proposed to have strong association with pancreatic 
and colorectal cancers. But this association is yet to be proven with accuracy. 
 
An issue of paramount importance that has to be considered is  the long term 
use of PPI for dyspepsia without screening and eradication of H.pylori can cause 
the following setbacks. 
 
• Prolonged use of PPI causes persistent hypergastrinemia due to G cell 
hyperplasia, which may cause Gastric Carcinoid.  
  
• Long term use alters the acid milieu of the antrum, which is the natural habitat 
of H.pylori, leading to migration of the bacteria more proximally to the 
fundus. This produces chronic fundic inflammation and intestinal metaplasia 
which has shown to cause fundic adenocarcinoma. Hence simple PPI therapy 
without H.pylori eradication , as commonly followed in clinical practice , can 
be detrimental or even dangerous to the patient. 
• PPI abolish the symptoms and hence patient compliance with a full course of 
H.pylori eradication therapy comes under duress. 
The widespread eradication of Helicobacter depends largely on the 
prevention of person to person transmission. Development of a prophylactic 
vaccine would open new avenues in the epic of Helicobacter pylori as a human 
pathogen from time immemorial. Finally, it is to be proved whether total 
eradication of this co-evolved pathogen is an absolute necessity or could prove 
detrimental in certain situations. 
COST OF THERAPY 
Vakil et al. after analyzing the cost effectiveness of various diagnostic modalities 
available for H.pylori concluded that the antibody testing incurred the lowest cost 
per correct diagnosis at all levels of prevalence compared to all other methods.53 
  
The argument of whether first to go for endoscopy in symptomatic cases or to go 
for empirical therapy followed by endoscopy if necessary in persistent cases still 
remains under question. Though the Markov Model clearly shows endoscopy as 
the second step, this fact remains in a developing country such as ours that 
Empirical therapy be started first. This is mainly due to the cost factors involved 
with Upper GI endoscopy.  
The cost of various anti-H.pylori kits available in the Indian market are as follows 
ULCIKIT Rs.26.00 Abbott India 
OMOXITIN Rs.13.84 USV Corvette 
LANSIKIT Rs.14.95 Zydus Cadilla 
OMEPRAZ HP KIT Rs.122.00 Alkem Labs 
HELIKIT Rs.24.16 Zydus Cadilla 
HELIPAC KIT Rs.25.00 Profic Organic 
OMEPRAN HP KIT Rs.25.00 Alkem Labs 
LOKIT Rs.27.50 Kopran Labs 
HP KIT Rs.33.00 Sun Pharma 
ZOVANTA KIT Rs.36.00 Dr.Reddy’s Lab 
PYLOMOX KIT Rs.37.00 Ranbaxy Labs 
OTC HP KIT Rs.49.50 Biochem Pharma 
  
LTC KIT Rs.60.00 Ind Swift 
HELIGO KIT Rs.63.25 Intas Pharma 
L-COT KIT Rs.55.36 Lupin Pharma 
Of all the drugs used in eradication of Helicobacter pylori, the drug Clarithromycin 
is the most expensive one. Its price for a single tablet varies from Rs.34 to Rs.69. 
ALEMBIC  Rs.34.20 
GLENMARK Rs.55.00 
ABBOTT INDIA Rs.56.30 
ZYDUS CADILLA Rs.68.75 
GLAXO Rs.69.20 
NOVARTIS Rs.34.00 
 
Though the drug Clarithromycin is highly effective against H.pylori, its exuberant 
cost limits its use in a country like our India.  
 
 
 
 
  
CONCLUSION 
Helicobacter pylori is one of the most successful colonizers of the human stomach 
of almost half the world’s population. But only a small fraction of individuals 
develop H.pylori associated diseases.  
From this study , the conclusions that can be drawn are as follows 
• Non –Invasive testing by serology is a sensitive and specific modality of 
testing for mass screening purposes. This is because of its good performance 
characteristics and technical simplicity. 
• Culture , microscopy and Rapid Urease Tests are the ‘gold standard’ in 
diagnosing H.pylori infection 
• Patients with endoscopically proven peptic ulcers have a 87.8% positivity in 
H.pylori serology testing.  
• Among acute presentation of perforative peritonitis, upto 59.5% are H.pylori 
positive. 
• 60% of Distal Gastric Carcinoma are seropositive. 
• Among those with Non-Ulcer dyspepsia, only 22% were positive. 
• Treatment of Helicobacter pylori should be initiated at the earliest in positive 
cases. Eradication drastically reduces the recurrence of ulcers. 
  
• Symptomatic management of gastritis with PPI alone without evaluation and 
eradication of H.pylori leads to proximal migration of the organism and 
proximal gastric cancers increase in incidence. 
• It is always best to start with a regimen which has either Amoxicillin or 
Clarithromycin but never both in the same course. This prevents 
development of double resistance. 
• 2 weeks therapy is far better than 1 week course. 
• Eradication should be assessed 4 to 6 week after completion of therapy. 
• Serology is not the ideal test to evaluate eradication. Eradication is to be 
proven by Urease Breath Test , Rapid Urease Test or by Stool Antigen 
assay. 
• Persistent infection heralds resistance and requires susceptibility testing and 
treatment with second line or other rescue regimen 
Helicobacter pylori infection is an ‘Ice Berg’ disease. The need of the hour is a 
well-targeted monotherapy that has least chance of leading to anti-microbial 
resistance. Helicobacter pylori is one of the most extensively studied bacteria in the 
history of human evolution and microbiology and yet it still remains the most 
difficult to comprehend and interpret. The Basic question of whether Helicobacter 
is a friend or foe still remains to be answered. 
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PHOTOGRAPHS AND IMAGES 
Fig 3 : Electron Micrographic picture of Helicobacter pylori 
 
 
 
 
 
 
 
Fig 4 : Electron Micrographic picture of H.pylori adherent to gastric mucosa 
 
 
 
 
 
  
Fig 5 : Electron Micrograph showing dense colonization of antral mucosa 
 
 
 
 
 
 
Fig 6 : Parts of the stomach 
 
 
 
 
 
 
 
  
Fig 7 : Cross Section of Stomach Wall 
 
 
 
 
 
 
 
Fig 8 : Vasculature , Lymphatics and Innervation of the Stomach 
 
 
 
 
 
 
  
Fig 9 : Gastric Gland 
 
 
 
 
Fig 10 : Development of the Foregut 
 
 
 
 
 
 
 
 
 
  
Fig 11 : H.pylori gastritis showing lymphocytic and Plasma cell infiltration 
 
 
 
 
 
 
Fig 12 : Ulcer along the Lesser curvature 
 
 
 
 
 
 
 
  
Fig 13 : Ulcer along the Greater Curvature 
 
 
 
 
 
 
Fig 14 : Duodenal Ulcer 
 
 
 
 
 
 
 
  
Fig 15 : Bleeding Duodenal Ulcer 
 
 
 
 
 
 
Fig 16 : Gastric Carcinoma 
 
 
 
 
 
 
 
  
Fig 1 : Serology Card showing Positive result 
 
 
 
 
 
Fig 2 : Serology Card Showing Negative result 
 
 
 
 
 
 
 
 
  
 
 BIBLIOGRAPHY 
1. International Agency for research on cancer- Schistosomes, Liver Flukes, 
Helicobacter pylori, IARC monographs on the evaluation of carcinogenic risk 
to humans. Vol 6 LYON:IARC;1994 
2. Rust M Schweinitzer T, Josenhans C (2008). “Helicobacter Flagella, Motility 
and Chemotaxis”. In Yamaoka Y. Helicobacter pylori: Molecular Genetics anad 
Cellular Biology. Caister Academic Press. 
3. Olson JW, Maier RJ (November 2002). “Molecular Hydrogen as an energy 
source for Helicobacter pylori”. Science 298(5599):1788-90 
4. Stark RM, Gerwig GJ, Pitman RS et al. (February 1999). “Biofilm formation ny 
Helicobacter pylori”. Lett Appl Microbiol 28(2): 121-6 
5. Chan WY, Huy PK, Leung KM, Chow J, Kwok F, Ng CS (October 1994). 
“Coccoid forms of Helicobacter pylori in the human stomach”. Am J Clin 
Pathol 102(4): 503-7 
6. Kusters JG, van Vliet AH, Kuipers EJ (July 2006). “Pathogenesis of 
Helicobacter pylori infection”. Clin Microbiol Rev 19(3): 449-90. 
 
  
7. Baldwin DN, Shepherd B, Kraemer P et al.(February 2007). “Identification of 
Helicobacter pylori genes that contribute to stomach colonization”. Infect 
Immun 75(2): 1005-16. 
8. Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ.”Helicobacter pylori 
and atrophic gastritis, Importance of cagA status. J NatlCancer 
Inst.1995;87:1777-1780 
9. Yamaoka Y, Kodama T, Kashima K, Graham DY, Sepulveda AR. “Variants of 
the 3’ region of cagA gene in Helicobacter pylori isolates from patients with 
different H pylori associated diseases. J Clin Microbiol.1998;36:2258-2263. 
10. Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori 
Vacuolating Cytotoxin inhibits T Lymphocyte activation. Science 
2003;301:1099-1102. 
11. Aras RA, Fischer W, Perez-Perez GI, Crosatti M, Ando T, Hass R, Blaser MJ,. 
Plasticuty of repetitive DNA sequences within a bacterial(Type IV) secretion 
system component. J Exp Med.2003;198:1349-1360. 
12. Kersulyle D, Chalkauskas H,Berg DE. Emergence of recombinant strains of 
Helicobacter pylori during human infection, Mol Microbiol, 1999;31:31-43. 
13. Pounder RE, Ng D(1995). “The prevalence of Helicobacter pylori infection in 
different countries” Aliment Pharmacol Ther.9 Suppl 2:33-9 
 
  
14. Franchini M, Veneri D. “Helicobacter pylori infection and Immune 
Thrombocytopenic Purpura:an update”.Helicobacter 2004;9:342-346. 
15. Rothenbacher D, Bode G, Berg G, Knayer U, Gonser T, Adler G, Brenner H. 
Helicobacter pylori among pre-school children and their parents:Evidence of 
parent-child transmission.J.Infect.Dis.1999;179:398-402 
16. Brenner H, Rotherbacher D, Bode G, Dieudonne P, Adler G. Active infection 
with Helicobacter pylori in healthy couples. Epidemiol.Infect.1999;122:91-95. 
17. Morris A, Nicholson G, Llyod G, Haines D, Rogers A, Taylor D. 
Seroepidemiology of Campylobacter pyloridis.N.Z.Med J 1986;99:657-659 
18. Fox JG. Non Human reservoirs of Helicbacter pylori. 
Akiment.Pharmacol.Ther.1995;9:93-103  
19. Dore MP, Sepulvaeda AR, Osato MS, Realdi G, Graham D.Y. Helicobacter 
pylori in sheep milk. Lancet 1999; 354:132 
20. Bode G, Rothenbacher D, Brenner H, Adler G. Pets are not a risk factor for 
Helicobacter pylori infection in young children-Results of a population based 
study in Southern Germany.Pediatr.Infect.Dis J.1998;17:909-912. 
21. Osato MS, Ayub K, Le HH, Reddy R, Graham DY. Houseflies are an unlikely 
resermoir or vector for Helicobacter pylori. J Clin Microbiol.1998;36: 2786-
2788 
 
  
22. Klein P.D, Graham DY, Gaillour A, Opekun A.R, Smith E.O. Water source as 
risk factor for Helicobacter pylori infection in Peruvian 
children.Gastrointestinal physiology workup group.Lancet 1991;337: 1503-
1506 
23. Clemens J, Albert MJ, Rao M, Huda S,Qudri F,Vanloon F.P.L, Pradhan 
B,Naficy A, Banik A. Sociodemographic, hygienic and nutritional correlates of 
Helicobacter pylori infection of young Bangladeshi children. Pediatr Infect Dis 
J.1996;15: 1113-1118 
24. Sasaki K, Tajiri Y, Sata M, Fuji Y, Matsubara F, Zhao MG, Shimuzu S, 
Toyonaga A, Tanikawa K. Helicobacter pylori in the natural environment. 
Scand.J.Infect.Dis.1999;31:275-280 
25. Kusters J, Gerrits MM, Vanstrijp J, Vanden C.coccoid forms of gelicobacter 
pylori are morphological manifestations of cell death. 
Infect.Immun.1997;65:3672-3679 
26. Lin SK, Lambert JR, Schembri MA, NicholsonL. Helicobacter pylori 
prevalence in endoscopists and medical staff. K.Gastroenterol.Hepatol 
1994;9:319-324 
 
  
27. Leung WK, Siu KLK, Kwok CKL, Chan SY, Sung R, Subg JJY. Isolation of 
Helicobacter pylori from vomitus of children and its implication in gastro oral 
transmission.Am.J.Gastroenterol.1999;94:2881-2884 
28. Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter 
pylori from healthy infected adults. JAMA 1999;282:2240-2245 
29. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the 
current prevalence of Helicobacter pylori infection.Gut.1994;35:742-745 
30. McCallion WA, Murray LJ, Bailie AG, Dalzell AM, Oreilly D, Bamford KB. 
Helicobacter pylori infection in children – relation with current household 
living conditions.Gut.1996;38:18-21 
31. Basso L, Beattie S, Lawlor S, Clune J, O’Morain C. A descriptive follow-up 
study on Helicobacter pylori infection before and after exposure to a war 
area.Eur.J.Epidemiol.1994;10:109-111 
32. Malaty HM, Engstrand L, Pederson NL, Graham DY. Helicobacter pylori 
infection- Genentic and environmental influences. Ann 
Inter.Med.1994;120:982-986  
33. Farthing MJ.Helicobacter pylori infection:An overview. Br Med 
Bull.1998;54:1-6 
 
  
34. Chey WD, Wong BC. Americal College of Gastroenterology guideline on the 
management of Helicobacter pylori infection. Am J Gastroenterol 
2007;102:1808-25 
35. Desai HG, Gill HH, Shankaran K, Mehta PR, Prabhu SR. Dental plaques:a 
permanent reservoir of Helicobacter pylori.Scand.J 
Gastroenterol.1991;26:1205-1208 
36. Nguyen A, Elzaatari F, Graham DY. Helicobacter pylori in the oral cavity. Oral 
Surg.Oral Med.Oral Pathol.Oral Radiol.Endodontics. 1995;79:705-709 
37. Plachly A, Kommerell. The growth of Helicobacter pylori is inhibited by 
intragastric bile acids.Gastroduodenal pathology and Campylobacter. ElSevier, 
The Nehterlands 
38. Ricci V, Zarrilli R, Romano M. Voyage of Helicobacter pylori in the human 
stomach:Odyssey of a bacterium. Digest Liv Dis. 2002;34: 2-8 
39. Mukhopadhyay AK, Kersulyte D,Berg DE. Distinctiveness of genotype of 
Helicobacter pylori in Calcutta, India. J Bacteriol 2000;182(11):3219-27 
40. Hoffelner H, Reider G, Haas R. Helicobacter pylori vaccine development. Int J 
Med.Microbiol;298:151-159 
41. Lee S, Shin Y, Hahm K.Phytoceuticals: mighty but ignored weapons against 
Helicobacter pylori.J of Digestive Diseases 9(3):129-139 
  
42. Wang KY, Li SN, Liu CS et al. Effect of iongestion of Lactobacillus containg 
yoghurt in subjects with colonization with Helicobacter pylori. Am J Clin 
Nutrition;80(3):737-741 
43. Fahey JW, Haristoy X, Dolan PM et al. Sulphoraphane inhibits intra cellular, 
extra cellular and antibiotic resistant strains of Helicobacter pylori and prevents 
benzopyrene induced stomach tumours. Proc.Natl.Acad.Sci.U.S.A.99(11):7610-
15 
44. Marshall BJ, Goodwin CS, Warren JR, Murray R.Prospective double blind trial 
of duodenal ulcer relapse after eradication of Helicobacter pylori.Lancet 
1988;2:1437-42 
45. Dhali GK, Garg PK, Sharma MP. Role of H pylori treatment in positive and 
cytoprotective drugs in negative. RCT in Asians.J Gastroenterol Hepatol 
1999;14:523-528 
46. The Maastricht Consensus Report; Ailment Pharmac Therapy 2000;16:167-180 
47. Uemura N, Okamoto S, Yamamoto S.et al. Helicobacter pylori infection and 
development of gastric cancer.N Engl J Med 2001;345:784-789 
48. Chan FK, Sung JJ, Chung SC. Randomised trial of eradicating Helicobacter 
pylori before NSAID therapy to prevet peptic ulcer. Lancet.1997;350:975-979 
  
49. Gillen D,Wirz AA, Ardille JE, McColl KEL. Rebound hypersecretioon after 
omeprazole and its relation to on-treatment acid suppression and Helicobacter 
status. Gastroenterology 1999;116:239-247 
50. Peitz U, Sulliga M, Wolle K et al. High rates of post therapeutic resistance 
after failure of macrolide nitroimidazole trilpe theapry to cure Helicobacter 
pylori infection: impact of second line therapies in a randomized study, Aliment 
Pharmacol Ther-2002;16:315-324. 
51. Geritts MM, Schuijffel D, van Zwet AA, Kuipers EJ, Vandenbrouck-Grauls 
CM. Alteration in penicillin binding protein 1A confers resistance to beta 
lactam antibiotics in Helicobacter pylori. Antimicrob Agents 
Chemother.2002;46:2229-33 
52. Di Mario F, Aragona G, Dal BN,et al. Use of bovine lactoferrin for 
Helicobacter pylori eradication.Dig Liver Dis 2003;35:706-711 
53. Vakil N,Rhew D, Soll A, Ofman JJ. The cost effectiveness of diagnostic testing 
strategies of Helicobacter pylori. Am J Gastroenterol 2000;95:1691-8 
54. Ngauyen AM, el-Zaatari FA, Graham DY. Helicobacter pylori in the oral 
cavity:A critical review of literature.Oral surg oral med oral pathol Raiol 
Endod. 1995;76:705-9 
55. M.Robinson.Proton pump inhibitors:update on their role in acid related 
gastrointestinal diseases:Review. Intl.Clin Prac.June 2005;59:709-715 
  
56. Chey, William; Wong, BC; Practice Parameters Committee of the American 
College of Gastroenterology (2007). "American College of Gastroenterology 
Guideline on the Management of Helicobacter pylori Infection". Am J 
Gastroenterol 102 (8): 1808–1825. 
57. Peng NJ, Lai KH, Liu RS, Lee SC, Tsay DG, Lo CC, Tseng HH, Huang WK, 
Lo GH, Hsu PI. (2001). "Clinical significance of oral urease in diagnosis of 
Helicobacter pylori infection by [13C]urea breath test". Dig Dis Sci 46 (8): 
1772–8.  
58. Furuta T, Sugimoto M, Shirai N, Ishizaki T, Cyp2C19 pharmacogenomaic 
associated with thera;y of Helicobacter pylori infection and gastro-esophageal 
reflux disease with a proton pump inhibitor. Pharmacogenomics 2007;8:1199-
210 
59. Sachs G, Shin JM, Howden CW (2006). "Review Article: The clinical 
pharmacology of proton pump inhibitors". Ailment. Pharmacol Ther. 23(2): 2–8 
60. Wesołowski, M. (1982). "Thermal decomposition of pharmaceutical 
preparations containing inorganic components". Microchimica 
Acta (Vienna) 77 (5–6): 451–464. 
61. Eisenstein, B. I.; Schaechter, M. (2007). "DNA and Chromosome Mechanics". 
In Schaechter, M.; Engleberg, N. C.; DiRita, V. J. et al.. Schaechter's 
  
Mechanisms of Microbial Disease. Hagerstown, MD: Lippincott Williams & 
Wilkins. p. 28. 
62. Abba-Aji A & Mulligan O. Psychosis Beware! A Case Series of 
Clarithromycin and Psychosis – Irish Journal of Psychological Medicine – 
Jun.2007.Vol.24 no2. P 79-80. 
63. Malhotra-Kumar, S.; Lammens, C.; Coenen, S.; Van Herck, K.; Goossens, H. 
(2007). "Effect of azithromycin and clarithromycin therapy on pharyngeal 
carriage of macrolide-resistant streptococci in healthy volunteers: A 
randomised, double-blind, placebo-controlled study". The Lancet 369 (9560): 
482–490.  
64. Tietz, A.; Heim, M. H.; Eriksson, U.; Marsch, S.; Terracciano, L.; Krähenbühl, 
S. (2003). "Fulminant liver failure associated with clarithromycin". The Annals 
of Pharmacotherapy 37 (1): 57–60. 
65. Nangia, A.; Biradha, K.; Desiraju, G.R. (1996) "Correlation of biological 
activity in β-lactam anitbiotics with Woodward and Cohen structural 
parameters: A Camridge database study." J Chem Soc, Perkin Trans 2 (5), 943–
53. 
  
66. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-esophageal 
reflux disease in patients with duodenal ulcer treated for Helicobacter pylori 
infection. Aliment Pharmocol Ther.2000:1445-51 
67. Phull PS, Halliday D, Price AB, Jacyna MR. Absence of dyspeptic symptoms 
as a test for Helicobacter pylori eradication. BMJ 1996;312:349-350 
68. Kousunen TU, Seppala K, Sarna S, Sipponestic P.Diagnostic value of 
decreasing IgG, IgA and IgM antibody titre after eradication of Helicobacter 
pylori. Lancet.1992;339: 893-895 
69. Feldmen M, Cryer B, Lee E, Peterson WL. Role of seroconversion ion 
confirming cure of Hellicobacter pylori infection. JAMA 1998;280: 363-365 
70. Evans D, Enans Jr, Graham DY, Klein PD. Sensitivity and specificity of 
serological testing for detection of Helicobacter pylori infection. 
Gastroenterology 96: 1004-1008 
71. Czinn HS, Carr HS, Speck WT. Diagnosis of gastritis caused by Helicobacter 
pylori in children by means of ELISA. Rev Infect Dis 1991;13(suppl 8) : 700-
703 
72. Cutler AF, Harstad S, Ma CK, Blaser MJ, Perez-Perez MJ, Schubert TT. 
Accuracy of invasive and non-invasive tests to diagnose Helicobacter pylori 
infection. Gastroenterology  1995;109:136-41 
  
73. Dojo M, Azuma T, SaitoT, Ohtani M, Muramatsu A, Kuriyama M. Effects of 
Cyp2C19 gene polymorphism on cure rates for Helicobacter pylori infection by 
triple therapy with proton pump inhibitors(omeprazole or rabeprazole) 
Amoxillin and clarithromycin in Japan. Dig Liver Dis 2001;33:671-675 
74. Sobala GM, Crabtree JA, Pentith B, Rathbone T.Screeing dyspepsia by 
serology to Helicobacter pylori. Lancet 338:94-96 
75. Pinaki Ghosh, Amit D.Kandhare, Kiran S,Raygude. Cigarette smoking and 
Helicobacter pylori infection: A meta analysis of literature. Der Pharmacia 
Lettre 2012;4(1):128-134 
76. Javed M, Amin K, Muhammad D, Hussain A, Mahmood N. Prevalence of 
Helicobacter pylori. Professional Med Sep 2010;17:431-439 
77. Yuki Obata, Shogo Kikuchi, Hiroto Miwa, Kiyoko Yagyu. Diagnostic accuracy 
of serological kits for Helicobacter pylori infection with the same assay system 
but different antigens in Japanese patient population. J Med  
Microbiol October 2003;52:889-892 
78. Miwa, H., Murai, T., Ohkura, R., Kawabe, M., Tanaka, H., Ogihara, T., Watanabe, 
S. & Sato, N. (1997). Effect of fasting subjects’ posture on 13C-urea breath test for 
detection of Helicobacter pylori infection. Helicobacter 2, 82–85. 
  
79. Gisbert JP, Legido J, García-Sanz I, Pajares JM. Helicobacter pylori and 
perforated peptic ulcer prevalence of the infection and role of non-steroidal 
anti-inflammatory drugs. Dig Liver Dis. 2004 Feb;36(2):116-20. 
80. Thijs JC, van Zwet AA, Thijs WJ, Oey HB, Karrenbeld A, Stellaard F, Luijt 
DS, Meyer BC, Kleibeuker JH. Diagnostic tests for Helicobacter pylori: a 
prospective evaluation of their accuracy, without selecting a single test as the 
gold standard.  The American Journal of Gastroenterology [1996, 91(10):2125-
2129] 
 
 
 
 
 
 
 
 
  
PROFORMA 
NAME                                 : 
AGE                         : 
SEX               : 
INPATIENT NO.             : 
COMPLAINTS                       : 
DURATION OF COMPLAINTS     : 
DIAGNOSIS                                 : 
PREVIOUS TREATMENT              : 
SMOKING / ALCOHOL USE         : 
H.PYLORI SEROLOGY                 :    
UPPER GI ENDOSCOPY                : 
 
 
 
 
  
 
  
 
MASTER CHART
No Name A/S IP No. Complaints Duration Diagnosis Previous Addictions Serology OGD
Treatment
1 Jeya Pandi 34/M 14217 Epigastric Pain 1 year Gastric Perforation OTC Antacids Smoker Negative Not Done
2 Kasinathan 45/M 77882 Pain Abdomen 15 years Acid Peptic Disease OTC Antacids Nil Positive Active Bulbar Ulcer
3 Palani 51/M 76290 Heart Burn 20 years Chr.DU with GOO Native Alcoholic Positive Deformed Duodenal Bulb
4 Veeranan 51/M 20914 Pain Abdomen 2 years Chr.DU with GOO OTC Antacids Smoker Positive Deformed Duodenal Bulb
5 Muthiah 50/M 82993 Pain Abdomen 8 days DU Perforation Nil Nil Negative Not Done
6 Ponram 60/M 9388 Pain Abdomen 1 day DU Perforation Nil Alcoholic Positive Not Done
7 Thiraviyam 35/M 3747 Pain Abdomen 2 days Du Perforation Nil Nil Positive Not Done
8 Gandhi 30/M 77135 Vomiting 15 days Chr.DU with GOO OTC Antacids Nil Positive Oesophagitis-Du Ulcer-GOO
9 Dinesh 36/M 75643 Heart Burn 6  months Non Ulcer Dyspepsia OTC Antacids Nil Positive Normal Study
10 Paramasivam 58/M 18782 Malena 7 days Acid Peptic Disease OTC Antacids Smoker Positive Deformed Duodenal Bulb
11 Ragupathi 70/M 63318 Pain Abdomen 5 days DU Perforation OTC Antacids Smoker Negative Not Done
12 Natarajan 38/M 3911 Pain Abdomen 6 months DU Perforation OTC Antacids Nil Positive Active DU
13 Raja 45/M 28134 Pain Abdomen 2 days DU Perforation Nil Smoker Negative Not Done
14 Murugesan 40/M 30782 Pain Abdomen 1 day DU Perforation OTC Antacids Nil Positive Not Done
15 Jeya Pandi 48/M 14217 Pain Abdomen 4 days Gastric Perforation Nil Nil Negative Not Done
16 Veeramakali 70/M 29780 Pain Abdomen 10 days Chr.DU with GOO OTC Antacids Nil Positive Deformed Duodenal Bulb
17 Andisamy 50/M 66641 Pain Abdomen 4 years Acid Peptic Disease Nil Smoker Positive Erosive Antral Gastritis
18 Vijayan 29/M 66630 Heart Burn 8 months Acid Peptic Disease OTC Antacids Nil Negative Bulbar DU Ulcer
19 Thangaraj 35/M 35680 Pain Abdomen 5 days DU Perforation Nil Smoker Negative Not Done
20 Sundarajan 50/M 44283 Pain Abdomen 5 years Chr.DU with GOO OTC Antacids Smoker Negative Active DU Ulcer
21 Nagaraj 36/M 22816 Epigastric Pain 2 years Acid Peptic Disease OTC Antacids Alcoholic Positive Oesophagitis with DU Ulcer
22 Kannan 29/M 24214 Heart Burn 1 year Acid Peptic Disease OTC Antacids Nil Positive Oesophagitis
23 Sakkarai 44/M 27884 Vomiting 1 month Chr.DU with GOO OTC Antacids Alcoholic Positive Deformed Duodenal Bulb
24 Pandi 58/M 30532 Vomiting 1 month Carcinoma Stomach Nil Smoker Positive Ulcer Growth Distal Stomach
25 Raja 35/M 30753 Pain Abdomen 2 days DU Perforation Nil Nil Negative Not Done
26 Murugesan 45/M 30782 Pain Abdomen 2 days DU Perforation OTC Antacids Alcoholic Positive Not Done
27 Sivalingam 53/M 74921 Epigastric Pain 7 days Acid Peptic Disease Nil Alcoholic Positive Active DU Ulcer
28 Ramanathan 40/M 30441 Pain Abdomen 2 days DU Perforation OTC Antacids Nil Positive Not Done
29 Saravanan 45/M 32158 Pain Abdomen 6 months Acid Peptic Disease OTC Antacids Nil Positive Active DU Ulcer
30 Vellaisamy 48/M 32384 Pain Abdomen 6 months Non Ulcer Dyspepsia Nil Nil Negative Normal Study
31 Bose 66/M 34230 Loss of Apetite 6 months Carcinoma Stomach Nil Alcoholic Positive Antral Growth
32 Venkatesh 36/M 36354 Epigastric Pain 2  months Acid Peptic Disease Nil Nil Negative Gastritis
33 Zahir Hussain 27/M 38111 Pain Abdomen 1 day DU Perforation OTC Antacids Nil Positive Not Done
34 Soundarapandi 45/M 45425 Loss of Apetite 1 month Carcinoma Stomach Nil Nil Negative Ulcer Growth Distal Stomach
35 Sevugamurthy 38/M 51599 Pain Abdomen 1 month Non Ulcer Dyspepsia OTC Antacids Nil Negative Normal Study
36 Sakthi 30/M 58383 Pain Abdomen 1 year Non Ulcer Dyspepsia OTC Antacids Nil Negative Normal Study
37 Arokiam 52/M 9244 Pain Abdomen 2 days DU Perforation Nil Nil Positive Not Done
38 Saravanan 30/M 70849 Heart Burn 6 months Acid Peptic Disease Nil Alcoholic Positive Deformed Duodenal Bulb
39 Thomas 38/M 61769 Loss of Apetite 1 month Carcinoma Stomach Nil Nil Negative Ulcer Growth Distal Stomach
40 Kannan 39/M 63377 Epigastric Pain 2 months Acid Peptic Disease OTC Antacids Nil Negative Duodinitis+Esophagitis
41 Chinnamannan 38/M 63614 Pain Abdomen 1 day DU Perforation Nil Nil Negative Not Done
42 Pandi 58/M 69636 Pain Abdomen 1 day DU Perforation Nil Nil Negative Not Done
43 Kulandaivel 30/M 71327 Vomiting 1 month Chr. DU with GOO OTC Antacids Alcoholic Positive Deformed Duodenal Bulb
44 Ayyavu 65/M 74420 Epigastric Pain 4 months Non Ulcer Dyspepsia OTC Antacids Nil Positive Normal Study 
45 Muneeswaran 30/M 81671 Epigastric Pain 1 month Non Ulcer Dyspepsia OTC Antacids Nil Negative Normal Study 
46 Murugan 55/M 81697 Pain Abdomen 6 months Acid Peptic Disease OTC Antacids Nil Negative Gastritis
47 Chellapanddi 29/M 777 Pain Abdomen 4 days DU Perforation Nil Smoker Positive Not Done
48 Veeran 45/M 3924 Pain Abdomen 2 days DU Perforation Nil Nil Negative Not Done
49 Ayyavu 62/M 7435 Pain Abdomen 1 day DU Perforation Nil Nil Positive Not Done
50 Padmanaban 55/M 7669 Pain Abdomen 2 days DU Perforation Nil Smoker Positive Not Done
51 Adaikalam 65/F 24961 Vomiting 1 month Chr.DU with GOO OTC Antacids Nil Positive Deformed DU Bulb
52 Sowmiya 19/F 32162 Pain Abdomen 2 months Non Ulcer Dyspepsia OTC Antacids Nil Negative Normal Study
53 Dhanalakshmi 50/F 39885 Pain Abdomen 3 months Acid Peptic Disease OTC Antacids Nil Negative Duodinitis
54 Sindhu 18/F 6114 Pain Abdomen 2 months Acid Peptic Disease OTC Antacids Nil Negative Gastritis
55 Janaki 52/F 6165 Epigastric Pain 1 month Acid Peptic Disease Nil Nil Positive Active Bulbar Ulcer
56 Sarasu 55/F 7177 Loss of Apetite 2 months Carcinoma Stomach Nil Nil Positive Growth Distal Stomach
57 Meenakshi 55/F 7209 Mass Abdomen 3 months Carcinoma Stomach Nil Nil Positive Antral Growth
58 Velammal 37/F 7446 Vomiting 1 month Chr.DU with GOO OTC Antacids Nil Positive Deformed DU Bulb
59 Murugeswari 28/F 7732 Pain Abdomen 1 month Acid Peptic Disease Nil Nil Positive Active Bulbar Ulcer
60 Jeya 51/F 10810 Vomiting 15 days Chr.DU with GOO OTC Antacids Nil Positive Deformed DU Bulb
61 Ponammal 62/F 14499 Pain Abdomen 2 days DU Perforation Nil Nil Positive Not Done
62 Sangammal 35/F 14995 Vomiting 20 days Chr.DU with GOO Nil Nil Positive Deformed DU Bulb
63 Asai 23/F 18040 Pain Abdomen 1 day DU Perforation Nil Nil Positive Not Done
64 Meena 46/F 26758 Mass Abdomen 1 month Carcinoma Stomach Nil Nil Negative Growth Distal Stomach
65 Kaliammal 48/F 14125 Vomiting 1 month Chr.DU with GOO Nil Nil Positive Deformed DU Bulb
66 Jeyashanthi 40/F 32637 Pain Abdomen 1 day DU Perforation OTC Antacids Nil Positive Not Done
67 Sivapackiam 40/F 38283 Vomiting 20 days Chr.DU with GOO Nil Nil Negative Deformed DU Bulb
68 Karugi 45/F 40006 Pain Abdomen 1 day DU Perforation Nil Nil Positive Not Done
69 Lalitha 55/F 42199 Pain Abdomen 1 day DU Perforation Nil Nil Negative Not Done
70 Bakiam 60/F 45279 Loss of Apetite 2 months Carcinoma Stomach Nil Nil Negative Growth Distal Stomach
71 Lakshmi 40/F 47177 Loss of Apetite 2 months Carcinoma Stomach Nil Nil Positive Growth Distal Stomach
72 Pechiammal 65/F 50689 Pain Abdomen 2 days DU Perforation OTC Antacids Nil Positive Not Done
73 Buvaneshwari 20/F 58987 Pain Abdomen 1 day DU Perforation OTC Antacids Nil Positive Not Done
74 Palaniammal 60/F 53303 Pain Abdomen 2 days DU Perforation OTC Antacids Nil Negative Not Done
75 Pichaimuthu 23/F 64961 Pain Abdomen 3 days DU Perforation OTC Antacids Nil Positive Not Done
76 Guruvammal 85/F 73070 Pain Abdomen 2 months Acid Peptic Disease OTC Antacids Nil Negative Antral Gastritis
77 Lillipushpam 43/F 88857 Vomiting 1 month Chr.DU with GOO OTC Antacids Nil Positive Cicatrised DU Bulb
78 Kambarbanu 38/F 72803 Heart Burn 6 months Acid Peptic Disease OTC Antacids Nil Positive Gastritis
79 Deivathammal 50/F 28362 Epigastric Pain 1 year Acid Peptic Disease OTC Antacids Nil Positive Active Bulbar Ulcer
80 Amutha 45/F 37472 Epigastric Pain 6 months Acid Peptic Disease OTC Antacids Nil Positive Active Bulbar Ulcer
81 Selvapriya 22/F 41159 Epigastric Pain 2 months Acid Peptic Disease OTC Antacids Nil Positive Active Bulbar Ulcer
82 Vanitha 28/F 43233 Pain Abdomen 1 year Acid Peptic Disease OTC Antacids Nil Positive Cicatrised DU Bulb
83 Muthulaxmi 39/F 38662 Pain Abdomen 3 days DU Perforation OTC Antacids Nil Negative Not Done
84 Pandiammal 21/F 16088 Pain Abdomen 1 day DU Perforation OTC Antacids Nil Positive Not Done
85 Shanmugavalli 30/F 53245 Pain Abdomen 2 days DU Perforation OTC Antacids Nil Positive Not Done
86 Rathnammal 37/F 54830 Pain Abdomen 1 day DU Perforation OTC Antacids Nil Negative Not Done
87 Palayi 60/F 58012 Vomiting 1 month Chr.DU with GOO Nil Nil Positive Cicatrised DU Bulb
88 Chellammal 63/F 51319 Vomiting 2 months Chr.DU with GOO OTC Antacids Nil Positive Deformed DU Bulb
89 Soundaravalli 29/F 54898 Pain Abdomen 2 days DU Perforation Nil Nil Positive Not Done
90 Mahalakshmi 27/F 114290 Epigastric Pain 3 weeks Acid Peptic Disease OTC Antacids Nil Negative Pangastritis
91 Tamilarasi 45/F 114558 Epigastric Pain 6 months Acid Peptic Disease OTC Antacids Nil Negative Antral Gastritis
92 Mariammal 45/F 79729 Pain Abdomen 3 days DU Perforation OTC Antacids Nil Negative Not Done
93 Meenakshi 50/F 79110 Epigastric Pain 3 months Carcinoma Stomach OTC Antacids Nil Positive Antral Growth
94 Ragupathy 70/F 93318 Pain Abdomen 5 days DU Perforation OTC Antacids Tobacco Positive Not Done
95 Arumugathal 62/F 24414 Hemetemesis 2 days Acid Peptic Disease OTC Antacids Nil Positive Prepyloric Ulcer + DU Ulcer
96 Sundarajam 50/F 44283 Pain Abdomen 5 years Chr.DU with GOO OTC Antacids Tobacco Negative Cicatrised DU Bulb
97 Said Ali Fatima 33/F 36925 Pain Abdomen 3 years Acid Peptic Disease OTC Antacids Nil Negative Antral Gastritis
98 Sathya 23/F 55991 Pain Abdomen 1 year Non Ulcer Dyspepsia OTC Antacids Nil Negative Normal Study
99 Deivanai 15/F 58908 Pain Abdomen 6 months Non Ulcer Dyspepsia OTC Antacids Nil Negative Normal Study
100 Sangumani 29/F 49639 Pain Abdomen 3 months Acid Peptic Disease OTC Antacids Nil Positive Active Bulbar Ulcer
